



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 129 847
B1

⑫

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of patent specification: 06.06.90

⑯ Int. Cl.⁵: C 07 D 487/04, A 61 K 31/505

⑰ Application number: 84107103.8

// (C07D487/04, 239:00,
231:00)

⑰ Date of filing: 20.06.84

④ Aryl and heteroaryl7-(aryl and heteroaryl)-pyrazolo-1,5-ar-pyrimidin-3-ylmethanones.

⑯ Priority: 23.06.83 US 506966

⑯ Proprietor: AMERICAN CYANAMID COMPANY
1937 West Main Street P.O. Box 60
Stamford Connecticut 06904-0060 (US)

⑯ Date of publication of application:
02.01.85 Bulletin 85/01

⑯ Inventor: Dusza, John Paul
24 Convent Road
Nanuet, NY 10954 (US)
Inventor: Tomcufcik, Andrew Stephen
48 Dearborn Drive
Old Tappan, NJ 07675 (US)
Inventor: Albright, Jay Donald
5 Clifford Court
Nanuet, NY 10954 (US)

⑯ Publication of the grant of the patent:
06.06.90 Bulletin 90/23

⑯ Representative: Wächtershäuser, Günter, Dr.
Tal 29
D-8000 München 2 (DE)

⑯ Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

⑯ References cited:
EP-A-0 025 819
DE-A-2 257 547
US-A-4 093 617
US-A-4 178 449

Journal of Medicinal Chemistry, vol. 20, no. 3,
1977, pages 386-393; Kirkpatrick et al.: "3-Halo-
5,7-dimethylpyrazolo (1,5-a) pyrimidines, a
Nonbenzodiazepinoid Class of Antianxiety
Agents Devoid of Potentiation of Central
Nervous System Depressant Effects of Ethanol
or Barbiturates"

EP 0 129 847 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.


BEST AVAILABLE COPY

Description**Summary of the Invention**

5 This invention relates to new organic compounds which are aryl or heteroaryl[7-(aryl or heteroaryl)-pyrazolo[1,5-*a*]pyrimidin-3-yl]methanones which are useful as anxiolytic or antiepileptic agents as well as sedative-hypnotic and skeletal muscle relaxant agents. This invention also relates to using the novel compounds, to compositions of matter containing them as the active ingredient and to processes for their production.

10 Detailed Description of the Invention

In accordance with this invention, the novel compounds are represented by the following structural formula:



wherein R₁ is selected from the group consisting of unsubstituted phenyl; phenyl mono- or di-substituted by halogen, alkoxy(C₁—C₃) or alkyl(C₁—C₃); phenyl mono-substituted by trifluoromethyl, alkylthio(C₁—C₃), alkylamino(C₁—C₃), dialkylamino(C₁—C₃), methylenedioxy, alkylsulfonyl(C₁—C₃) or alkanoylamino(C₁—C₃); naphthalenyl; thiazolyl; biphenyl; thiienyl; furanyl; pyridinyl; substituted thiazolyl; substituted biphenyl; substituted thiienyl; and substituted pyridinyl wherein the substituents are selected from one or two of the group consisting of halogen, alkoxy(C₁—C₃) and alkyl(C₁—C₃); R₂, R₄ and R₅ are each selected from the group consisting of hydrogen and alkyl(C₁—C₃); and R₃ is selected from the group consisting of unsubstituted phenyl, phenyl mono-substituted by halogen, trifluoromethyl, alkoxy(C₁—C₃), amino, alkyl(C₁—C₃), alkylamino(C₁—C₆), dialkylamino(C₁—C₃), alkanoylamino(C₁—C₆), N-alkyl(C₁—C₆)alkanoyl-amino(C₁—C₆), cyano or alkylthio(C₁—C₃); furanyl; thiienyl; pyridinyl; and pyridyl-1-oxide.

30 The most preferred compounds of this invention of particular interest are those compounds of the above formula wherein R₃ is 3-(trifluoromethyl)phenyl, 3-pyridinyl or 4-pyridinyl especially when R₁ is 2-furanyl and R₂, R₄ and R₅ are each hydrogen. Also, the compounds of major interest are selected from the above formula wherein R₃ is 3-(trifluoromethyl)phenyl, 3-pyridinyl, 4-pyridinyl, 3-[N-alkyl(C₁—C₆)alkanoylamino(C₁—C₆)]phenyl or 3-[alkylamino(C₁—C₆)]phenyl, when R₁ is unsubstituted phenyl; phenyl substituted by 4-methyl, 4-ethyl, 4-methoxy, 3,4-dimethoxy or 4-dimethylamino; 2-furanyl; 2-thienyl; 2-pyridinyl; or 4-pyridinyl; and R₂, R₄ and R₅ are each hydrogen.

35 Other representative compounds of the invention herein are as follows:


40 2-furanyl[7-(2-furanyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 2-furanyl[7-(2-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 [7-(2-furanyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]-2-pyridinyl-methanone
 [7-(2-furanyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]-3-pyridinyl-methanone
 [7-(2-furanyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]-4-pyridinyl-methanone
 [4-(dimethylamino)phenyl][7-(2-furanyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 50 2-thienyl[7-(2-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 3-pyridinyl[7-(2-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 [4-(dimethylamino)phenyl][7-(2-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 2-furanyl[7-(3-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 2-thienyl[7-(3-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 55 3-pyridinyl[7-(3-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 4-pyridinyl[7-(3-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 [4-(dimethylamino)phenyl][7-(3-thienyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (3,4-dimethylphenyl)[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (3,4-dimethylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 60 (3,4-dimethylphenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (4-dimethylaminophenyl)[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (4-dimethylaminophenyl)[7-(3-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (4-dimethylaminophenyl)[7-[3-trifluoromethyl]phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 65 2-thiazolyl[7-[3-trifluoromethyl]phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone
 (5-methyl-2-thienyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

EP 0 129 847 B1

(5-methyl-2-thienyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methyl-2-thienyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-thienyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-thienyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-thienyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-bromo-2-thienyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-bromo-2-thienyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-bromo-2-thienyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-chloro-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-chloro-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-chloro-2-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-fluoro-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-fluoro-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-fluoro-2-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-chloro-2-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-fluoro-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-fluoro-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-methyl-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-methyl-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-methyl-2-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methyl-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (2-fluorophenyl)[7-(3-trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (2-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (2-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methyl-3-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methyl-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methyl-3-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (6-methyl-3-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (6-methyl-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (6-methyl-3-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-thienyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 [7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-3-thienylmethanone
 (3-furanyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-furanyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-methoxy-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (3-methoxy-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (4-methoxy-2-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (4-methoxy-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (4-methoxy-2-pyridinyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (4-methyl-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (4-fluoro-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methoxy-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-fluoro-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-ethoxy-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-ethoxy-2-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (5-methoxy-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (6-methoxy-3-pyridinyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 (6-methoxy-3-pyridinyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 4-pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
 4-pyridinyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone

The instant invention is additionally concerned with the methods of treating anxiety or epilepsy and inducing a sedative-hypnotic or skeletal muscle relaxation effect in mammals employing the above-described compounds, to compositions of matter containing these compounds and processes for their production.

The novel compounds of this invention may be readily prepared as set forth in the following reaction scheme:



35 wherein R_1 , R_2 , R_3 , R_4 , and R_5 are as described above. The reaction of an appropriately substituted pyrazole (1) and an appropriately substituted 3-dimethylamino-1-(aryl) or (heteroaryl)-2-propen-1-one (2) under neutral or acidic conditions, such as glacial acetic acid at 20—150°C, preferably at reflux temperature, for 1—10 hours, followed by solvent removal, partitioning of the residue between saturated aqueous sodium bicarbonate and methylene chloride, passage of the organic layer through hydrous magnesium silicate and the addition of hexane to the refluxing eluate produces the desired products (3).

40 Products where R_3 is a pyridine-1-oxide may be prepared by treating the compounds (3) where R_3 is pyridine with *m*-chloroperbenzoic acid in methylene chloride with stirring for several hours, collecting the solid, slurring it in saturated aqueous sodium bicarbonate and boiling in water.

45 The substituted 3-dimethylamino-1-(aryl) or (heteroaryl)-2-propen-1-ones (2) are disclosed in one or more of U. S. Patents 4,178,449; 4,281,000; and 4,236,005.


The substituted pyrazoles (1) are the subject of the simultaneously filed patent application by the applicant with the title "(3-Amino-1H-pyrazol-4-yl)(aryl)methanones" (EPO application No. 84107102.0, filed June 20, 1984).

50 Pyrazolo[1,5-*a*]pyrimidines are prepared by condensation of 3-aminopyrazoles and substituted 3-aminopyrazoles with 1,3-dicarbonyl compounds as described in J. Med. Chem., 18, 645 (1974); J. Med. Chem., 18, 460 (1975); J. Med. Chem., 20, 386 (1977); Synthesis, 673 (1982) and references contained therein.

55 The 7-aryl and 7-heteroaryl[1,5-*a*]pyrimidines of this invention, which contain a 3-aryl group, are synthesized by condensation of 1-aryl or 1-heteroaryl-1,3-dicarbonyl compounds with 3-amino-4-aryloylpyrazoles.

The 3-aryl-1,3-dicarbonyl compounds useful in condensations with the appropriate 3-amino-4-aryloylpyrazoles are represented by the following structural formulae (4 to 8):

EP 0 129 847 B1



30 wherein R_4 and R_5 are hydrogen or alkyl(C_1-C_3); R_6 is alkyl(C_1-C_6), cyclohexyl, cyclopentyl, phenyl, or $-(\text{CH}_2)_m$ -phenyl where m is an integer 1-3; X is chloro, bromo, OR₇ or SR₇, where R₇ is alkyl(C_1-C_6); Z is SR₇, OR₈, NR₉R₁₀ or NHR₆ wherein R₈ is hydrogen, alkyl(C_1-C_{10}), $-(\text{CH}_2)_n$ -phenyl where n is an integer 1-3, alkanoyl(C_2-C_{10}), benzoyl or carboalkoxy(C_2-C_{10}); and R₉ and R₁₀ are individually selected from hydrogen, alkyl(C_1-C_{10}), phenyl and when taken together with the nitrogen atom to which they are attached form




40 where p is an integer of 4-6, or



45 where G is $-\text{O}-$ or $-\text{N}-\text{D}$, where D is alkyl(C_1-C_6), benzyl, benzoyl or alkanoyl(C_2-C_7).

The structure represented by formula (4) is a 1-aryl-1,3-dicarbonyl derivative which may enolize to give two enol structures represented by formula (4a) and (4b). The extent of enolization is dependent on the substituent R₅. When R₅ is hydrogen, the structure (4) represents an α -formyl ketone derivative which exists principally as the enolized form (4a). Such hydroxymethyleneketones (4a) are prepared by formylation of arylketones (6) with alkali metal alkoxides and alkyl formates such as methyl formate, ethyl formate and the like. The preparation of hydroxymethyleneketone is illustrated in Scheme 1.

The intermediate alkali metal salts of hydroxymethyleneketones (10) can be acylated by reaction with acid chlorides or anhydrides such as alkanoyl chlorides, benzoyl chloride, alcanoic acid anhydrides or benzoic anhydride to give O-acyl derivatives (12). Neutralization of the alkali metal salts (10) with acids such as acetic acid, hydrochloric acid and the like affords hydroxymethyleneketones (11). Either the alkali metal salts (10), the hydroxymethyleneketones (11), or the O-acylated derivatives (12) of hydroxymethyleneketones may be condensed with 3-amino-4-arylpyrazoles (1), under acidic or neutral conditions, in inert solvents, to give the novel 3-aryl-7-aryl(or heteroaryl)pyrazolo[1,5-a]pyrimidines (13) of this invention wherein R₄ is hydrogen or alkyl(C_1-C_3) and R₅ is hydrogen.

Scheme 1


$\text{R}_4 = \text{hydrogen or alkyl(C}_1\text{--C}_3\text{)}$

$\text{R}_5 = \text{hydrogen}$

EP 0 129 847 B1

The hydroxymethyleneketones (11) may be converted by the procedure of Scheme 2 to other aldehyde equivalents such as alkoxy methylene ketones (14), alkylthiomethylene ketones (15), or aminomethylene ketones (16). These aldehyde equivalents of hydroxymethylene ketones on condensation with 3-amino-4-arylpyrazoles give 3-aryl-7-aryl(heteroaryl)pyrazolo[1,5-a]pyrimidines (13), wherein R₄ is hydrogen or alkyl(C₁—C₃) and R₅ is hydrogen.

Scheme 2



R_4 = hydrogen or alkyl (C_1-C_3)

$R_5 \equiv$ hydrogen


EP 0 129 847 B1

Thus, hydroxymethyleneketones and derivatives which are chemical equivalents of hydroxymethyleneketones react under acidic or neutral conditions with 3-amino-4-arylpyrazoles to give novel 3-aryl(or heteroaryl)pyrazolo[1,5-a]pyrimidines.

Other intermediates which are chemical equivalents of hydroxymethyleneketones (11) are 3-(dialkylamino)-1-aryl or (heteroaryl)-2-propen-1-ones (17). Such N,N-(dialkylamino)methyleneketones (enaminones) (17) are prepared by reaction of arylketones (9) with N,N-dimethylformamide-dialkoxyacetals or N,N-dimethylacetamidedialkoxyacetals. Other acetals of N,N-dialkylformamides or acetals of N,N-dialkylacetamides, such as N,N-diethylformamide-dimethoxyacetal, N,N-dibutylformamide-diethoxyacetal, N,N-diethylacetamide-diethoxyacetal and the like may also be used in reactions with arylketones (9) to give aminomethylene ketone derivatives (17), (20) and (21). These derivatives are chemical equivalents of hydroxymethyleneketones (a-formylketones) and they react with 3-amino-4-arylpyrazoles (1) to give 3-aryl-7-aryl(or heteroaryl)pyrazolo[1,5-a]pyrimidines as shown in Scheme 3.

The reactions in Scheme 3 illustrate the methods for synthesizing derivatives with an alkyl group at the C-5 position [R₅, formula (23)] or at the C-6 position [R₄, formula (18)] of the pyrazolo[1,5-a]pyrimidine nucleus. This method also allows the preparation of derivatives (22) wherein R₄ and R₅ in formula (13) are both hydrogen. The reaction of ketones (9) and (19) with acetals of N,N-dialkylformamides or acetals of N,N-dialkylacetamides can be carried out in inert solvents or without a solvent.





Scheme 3



55

60

65




$\text{R}_5 = \text{alkyl}(\text{C}_1-\text{C}_3)$




55 3-Aryl-3-chloroacroleins (24) may also be used as intermediates for the condensation of 3-amino-4-
aryloxy- or heteroaryloxy-pyrazoles to give pyrazolo[1,5-*a*]pyrimidines as described in Scheme 4. The
intermediates (24) are synthesized by the reaction of aryl ketones (9) with *N,N*-dimethylformamide-
phosphorus oxychloride (Vilsmeier reagent) as described by J. A. Virgilio and E. Heilweil, Org. Prep.,
Proced. Int. 14 (1-2), pp 9-20 (1982) and references cited therein, and M. Weissenfels, et al., Z. Chem., 6,
471 (1966).

60 The reaction involves a formulation of the ketone followed by chlorination of the initially formylated
product. Alternatively, reaction of *N,N*-dialkylaminomethyleneketones (enaminones) (17) with *N,N*-
dimethylformamide-phosphorus oxybromide affords intermediates (25) which give, on hydrolysis, 3-aryloxy-
3-chloroacroleins (24). Substitution of phosphorus oxybromide for phosphorus oxychloride in the reactions
of Scheme 4 affords the corresponding 3-aryloxy-3-bromoacroleins which may also be condensed with 3-
amino-4-aryloxy- or heteroaryloxy-pyrazoles to give pyrazolo[1,5-*a*]pyrimidines. The intermediates (25) may be
reacted with 3-amino-4-aryloxy- or heteroaryloxy-pyrazoles to afford pyrazolo[1,5-*a*]pyrimidines (18).

Scheme 4



R₄ = hydrogen, alkyl (C₁–C₃)




1-Aryl-1,3-diketones illustrated by structural formula (26) as shown in Scheme 5, react with dialkylamines such as pyrrolidine, dimethylamine, diethylamine and the like to form enaminoes (27).


EP 0 129 847 B1

Reaction of compounds of structure type (27) with 3-amino-4-arylpyrazoles (1) under acidic reaction conditions gives pyrazolo[1,5-*a*]pyrimidines (28).

5 Scheme 5



1-Aroyl-1-propynones (29) react with 3-amino-4-arylpyrazoles (1) in alkanols such as methanol, ethanol, propanol, butanol and the like under catalysis with acids such as p-toluenesulfonic acid, acetic acid, boron trifluoride and the like at 50 to 100°C to give 7-arylpyrazolo[1,5-*a*]pyrimidines (30) as shown in scheme 6. Other suitable solvents for the reaction are benzene, toluene, xylene, dimethylformamide, dimethylacetamide, tetrahydrofuran, dioxane and the like.

Scheme 6

5 The preferred reaction conditions for condensation of hydroxymethylene ketones (11), 3-
 10 (dialkylamino)-1-aryl(or heteroaryl)-2-propen-1-one (17) and the like with 3-amino-4-arylpypyrazoles (1) are heating at 80—130°C in glacial acetic acid for 1—10 hours. Alternatively, the condensation reactions may be
 15 carried out with inert cosolvents in the presence of glacial acetic acid. Suitable solvents are dioxane, tetrahydrofuran, toluene, xylene, chloroform, carbon tetrachloride and the like. The novel pyrazolo-[1,5-*a*]pyrimidines of this invention may also be prepared by reaction of 3-amino-4-arylpypyrazoles with an appropriate 3-alkoxy, 3-hydroxy, 3-acetoxy, 3-alkylthio, or 3-benzoyloxy-1-(aryl or heteroaryl)-2-propen-1-one in inert organic solvents such as lower alkanols, dioxane, tetrahydrofuran, toluene and the like at the reflux temperature thereof and with or without 1 to 10 equivalents of an acid as catalyst. Suitable acid catalysts are glacial acetic acid, hydrochloric acid, trifluoroacetic acid and the like.

20 The novel compounds of the present invention possess central nervous system activity at nontoxic doses and as such are useful as anxiolytic agents. That is, they produce certain responses in standard tests with laboratory animals which are known to correlate well with relief of anxiety in man. Furthermore, these compounds have been shown by biological data to be useful as antiepileptic agents, particularly in the treatment of grand mal seizures as well as sedative-hypnotic and skeletal muscle relaxant agents.

25 The anti-anxiety and anticonvulsant properties of the novel compounds of the present invention have been established in a test which indicates anxiolytic and antiepileptic activity by the measure of protection from convulsions resulting from the administration of pentylenetetrazole. Single or graded dose levels of the test compounds were administered orally or intraperitoneally in a 2% starch vehicle, containing 0.5% v/v polyethylene glycol and one drop of Polysorbate 80 to groups of at least 4 rats. At 30 or 60 minutes, the rats were treated intravenously with pentylenetetrazole at a dose of 23 mg/kg of body weight. This dose is estimated to cause clonic seizures in 99% of unprotected rats. It has been reported [R. T. Hill and D. H. Tedeschi, "Animal Testing and Screening Procedures in Evaluating Psychotropic Drugs" in "An Introduction to Psychopharmacology", Eds. R. R. Rech and K. E. Moore, Raven Press, New York, pp 237—288 (1971)] that there is a high degree of correlation between antagonism of pentylenetetrazole seizures in rats and anti-anxiety or anticonvulsant effects in higher warm-blooded animals. The results of this test on representative compounds of the present invention are shown in Table I.

50

55

60

65

TABLE I

Protection Against Clonic Seizures Caused by
Pentylenetetrazole in Rats

Compound	Dose mg/kg	% of Rats Protected
phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	25.0	100
(4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	25.0	100
phenyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(4-fluorophenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	12.5	38
(4-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	63
[7-(3,4-dimethoxyphenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl](4-fluorophenyl)methanone	25.0	25
-2-thienyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
2-furanyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-thienyl-methanone	25.0	75
2-furanyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
2-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100

TABLE I (continued)

Compound	Dose mg/kg	% of Rats Protected
[2-methyl-7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	50
[7-(3,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	25
(4-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(4-methylphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(4-methylphenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	50
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone, pyridine-1-oxide	25.0	100
2-pyridinyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	75
2-pyridinyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	100
2-pyridinyl[7-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(3-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	100
[7-(3,5-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	25

TABLE I (continued)

Compound	Dose mg/kg	% of Rats Protected
(3-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(4-fluorophenyl)[7-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(2-chlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(4-fluorophenyl)[7-(2-fluorophenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(4-fluorophenyl)[5-methyl-7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	25.0	25
(4-fluorophenyl)[7-[4-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	50
4-[3-(4-fluorobenzoyl)pyrazolo[1,5-a]-pyrimidin-7-yl]benzonitrile	25.0	50
[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl](3,4,5-trimethoxyphenyl)-methanone	25.0	25
[6-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	100
(6-methyl-7-phenylpyrazolo[1,5-a]-pyrimidin-3-yl)phenyl-methanone	25.0	25
3-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl](3,4,5-trimethoxyphenyl)-methanone	25.0	25

TABLE I (continued)

Compound	Dose mg/kg	% of Rats Protected
(3,4-dimethoxyphenyl) [7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	87
(3,4-dimethoxyphenyl) [7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(3,4-dimethoxyphenyl) [7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	75
(3-methylphenyl) [7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(3,4-dimethoxyphenyl) [7-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(3-methylphenyl) [7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(3-methylphenyl) [7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(3-methylphenyl) [7-(3-methylphenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(4-chlorophenyl) [5-methyl-7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
[5-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone, pyridine-1-oxide	25.0	25
[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-pyridinyl-methanone	25.0	50
(4-fluorophenyl) [7-(4-fluorophenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	75
(4-methoxyphenyl) [7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100

TABLE I (continued)

Compound	Dose (mg/kg)	% of Rats Protected
[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]methanone	25.0	25
(4-methoxyphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(3-methoxyphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(3-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	75
[4-(trifluoromethyl)phenyl][7-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(3-chlorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(3-chlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
[7-(3,4-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl][4-(trifluoromethyl)phenyl]methanone	25.0	50
(4-fluorophenyl)[6-methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	75
(3-chlorophenyl)[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2,5-dichlorophenyl)[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2,5-dichlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2,5-dichlorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25

TABLE I (continued)

Compound	Dose (mg/kg)	% of Rats Protected
[7-[4-(methylthio)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]phenylmethanone	25.0	50
(2-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2-methylphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2-chlorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
(2-methylphenyl)[7-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
4-pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
4-pyridinyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-4-pyridinylmethanone	25.0	75
2-pyridinyl[7-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
[4-(dimethylamino)phenyl][7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[4-(dimethylamino)phenyl][7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	75
[4-(dimethylamino)phenyl][7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[2-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenylmethanone	25.0	25

TABLE I (continued)

Compound	Dose (mg/kg)	% of Rats Protected
[6-methyl-7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-phenylmethanone	25.0	25
(2-methoxyphenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	75
1,3-benzodioxol-5-yl[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	50
1,3-benzodioxol-5-yl[7-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	25
(4-ethoxyphenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	25
2-naphthalenyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	25
2-thienyl[7-[4-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	25
[7-(3-fluorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-2-thienylmethanone	25.0	25
[7-(4-fluorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl](2-methoxyphenyl)-methanone	25.0	50
(5-methyl-2-thienyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	25
3-thienyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	75
[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-3-thienylmethanone	25.0	50

TABLE I (continued)

Compound	Dose (mg/kg)	% of Rats Protected
(4-ethylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-3-thienylmethanone	25.0	50
(2-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
(2-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	100
(2-fluorophenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	50
phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone, pyridine-1-oxide	25.0	25
(4-methoxyphenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone, pyridine-1-oxide	25.0	25
[7-[3-(ethylamino)phenyl]pyrazolo-[1,5-a]pyrimidin-3-yl]-2-furanyl-methanone	25.0	100
[7-[3-(ethylamino)phenyl]pyrazolo-[1,5-a]pyrimidin-3-yl]phenylmethanone	25.0	100

TABLE I (continued)

5	Compound	Dose (mg/kg)	% of Rats Protected
10	N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylpropanamide	6.0	100
15	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylpropanamide	0.8	100
20	N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide	25.0	100
25	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide	0.8	75
30	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylpropanamide	12.5	100
35	N-ethyl-N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide	12.5	100
40	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide	6.2	100

45 Another test which has been used to assess antianxiety effects is a nonconditioned passive avoidance procedure described by J. R. Vogel, B. Beer and D. E. Clody, "A Simple and Reliable Conflict Procedure for Testing Anti-Anxiety Agents", *Psychopharmacologia*, 21, 1-7 (1971). A conflict situation is induced in rats by a modification of this method.

50 Groups of 6 naive, Wistar strain rats, weighing 200-240 g each were deprived of water for 48 hours and food for 24 hours. The test compounds were administered in single or graded, oral or intraperitoneal doses, suspended in a 2% starch vehicle containing 0.5% v/v polyethylene glycol and one drop of polysorbate 80. Control animals received the vehicle alone. At 30 to 60 minutes each rat was placed in an individual plexiglass chamber. Water was available *ad libitum* from a tap located in the rear of the chamber. A 0.7 milliampere DC shocking current was established between the stainless steel grid floor and the tap. After 20 licks of non-shocked drinking, a shock was delivered for 2 seconds and then further shocks were delivered on a ratio of one shock for 2 seconds for every 20 licks. This was continued for a total of 3 minutes. The number of shocks taken by each rat during the 3 minute interval was recorded and compared to a control group. The test compounds are considered active if the number of shocks received by the test group is significantly higher than the control group by the Mann-Witney U test. Results of this test on representative compounds of this invention appear in Table II.

60

65

TABLE II

Nonconditioned Passive Avoidance Test in Rats

Compound	Dose mg/kg	Result
phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	25.0	Active
(4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	25.0	Active
phenyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(4-fluorophenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	Active
(4-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]-methanone	25.0	Active
2-thienyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
2-furanyl[7-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
2-furanyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
2-furanyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
4-pyridinyl[7-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active

TABLE II (continued)

Compound	Dose mg/kg	Result
(4-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(4-methylphenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	12.5	Active
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone, pyridine-1-oxide	25.0	Active
2-pyridinyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
2-pyridinyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	Active
2-pyridinyl[7-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(3-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
[7-(4-fluorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	25.0	Active
(3-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(2-chlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
[6-methyl-7-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]phenyl-methanone	25.0	Active
3-furanyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active

TABLE II (continued)

Compound	Dose (mg/kg)	Result
4-pyridinyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(3-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
4-pyridinyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	Active
[4-(dimethylamino)phenyl][7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	Active
[4-(dimethylamino)phenyl][7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
1,3-benzodioxol-5-yl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-3-thienylmethanone	25.0	Active
(4-ethylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(2-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(2-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(2-fluorophenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	25.0	Active
[7-[3-(ethylamino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-2-furanylmethanone	25.0	Active
[7-[3-(ethylamino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]phenylmethanone	25.0	Active

TABLE II (continued)

Compound	Dose mg/kg	Result
(3,4-dimethoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(3-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(4-chlorophenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-pyridinyl-methanone	25.0	Active
(4-fluorophenyl)[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25.0	Active
(4-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	12.5	Active
N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylpropanamide	25.0	Active
N-ethyl-N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-propanamide	12.5	Active
N-[4-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide	25.0	Active
N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylpropanamide	1.5	Active
N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide	25.0	Active
N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide	3.1	Active
N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylpropanamide	12.5	Active

TABLE II (continued)

5	Compound	Dose mg/kg	Result
10	N-ethyl-N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-acetamide	12.5	Active
15	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide	25.0	Active

Another test utilized for the determination of anxiolytic activity is the measurement of the ability of test compounds to inhibit the binding of tritiated benzodiazepines to brain-specific receptors of warm-blooded animals. A modification of the method described by R. F. Squires, *et al.*, *Nature*, 266, No. 21, p732 (April, 1977) and H. Mohler, *et al.*, *Science*, 198, p849 (1977) was employed.

Male albino rats (Wistar strain, weighing 150—200 g each) were obtained from Royalhart Farms. ³H-Methyl-diazepam (79.9 Ci/mmol) and ³H-methyl-flunitrazepam (84.3 Ci/mmol) were obtained from New England Nuclear. The test compounds were solubilized in either dimethylformamide, acetic acid, ethanol or hydrochloric acid.

Whole cortex of rats was homogenized gently in 20 volumes of ice-cold 0.32 M sucrose, centrifuged twice at 1000 g for 10 minutes and then recentrifuged at 30,000 g for 20 minutes to produce a crude P₂-synaptosomal fraction. The P₂-fraction was either: (1) resuspended in twice the original volume in hypotonic 50 mM Tris.HCl (pH 7.4), or (2) resuspended in one-half the original volume in hypotonic 10 mM Tris.HCl (pH 7.4) and frozen (-20°C) until time of use. Frozen P₂ preparations were thawed and resuspended in four times the original homogenizing volume at time of assay.

The binding assay consisted of 300 μ l of the P₂-fraction suspension (0.2—0.4 mg protein), 100 μ l of test drug and 100 μ l of ³H-diazepam (1.5 nM, final concentration) or ³H-flunitrazepam (1.0 nM, final concentration) which was added to 1.5 ml of 50 mM Tris.HCl (pH 7.4). Nonspecific binding controls and total binding controls received 100 μ l of diazepam (3 μ M, final concentration) and 100 μ l of deionized water, respectively, in place of the test compound. Incubation for 30 minutes proceeded in ice and was terminated by filtration, under vacuum, through Whatman GF/C glass fiber filters. The filters were washed twice with 5 ml of ice-cold 50 mM Tris.HCl (pH 7.4) and placed in scintillation vials. After drying at 50—60°C for 30 minutes, 10 ml of Beckman Ready-SolvTM HP (a high performance pre-mix scintillation cocktail, registered trademark of Beckman Instruments, Inc., Irvine, California 92713) was added and the radioactivity determined in a scintillation counter.

Inhibition of binding was calculated by the difference between total binding and binding in the presence of test compound, divided by the total binding, \times 100.

The results of this test on representative compounds of the present invention are given in Table III.

45

50

55

60

65

TABLE III

Inhibition of the Binding of ^3H -Benzodiazepine
to Brain-Specific Receptors of Rats

Compound	% Inhibition
phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	45
phenyl(7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)methanone	55
phenyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	93
(4-fluorophenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	50
(4-fluorophenyl)(7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)methanone	42
[7-(3,4-dimethoxyphenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl](4-fluorophenyl)methanone	48
[3-(trifluoromethyl)phenyl][7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	56

TABLE III (continued)

Compound	% Inhibition
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]methanone	38
[5-methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	15
phenyl[7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	24
2-thienyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	99
2-furanyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	19
(7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)-[3-(trifluoromethyl)phenyl]methanone	19
[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-thienyl-methanone	82
[7-(2-furanyl)pyrazolo[1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]methanone	36
2-furanyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	98
2-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	72
[7-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-furanyl-methanone	34
2-furanyl(7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)methanone	81

TABLE III. (continued)

Compound	% Inhibition
[2-methyl-7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	52
[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]methanone	99
4-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	11
(2-methyl-7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl)phenyl-methanone	54
[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-thienyl-methanone	62
phenyl[7-(2-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	96
phenyl[7-(2-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	30
[7-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	95
[5-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	93
[7-[2-chloro-5-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	86
[7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	88

TABLE III (continued)

Compound	% Inhibition
phenyl[7-(3-thienyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	96
[7-[3-(methylthio)phenyl]pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	98
[7-(3,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	97
(4-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	56
(4-methylphenyl)[7-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	13
(4-methylphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	19
(4-methylphenyl)[7-(3-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	58
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone, pyridine-1-oxide	39
2-pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	98
2-pyridinyl[7-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	77
2-pyridinyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	93
2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	29

TABLE III (continued)

Compound	% Inhibition
(4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone, pyridine-1-oxide	15
2-pyridinyl[7-(2-thienyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	24
[7-(2,5-dichlorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	21
[7-(4-fluorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	18
[7-(3,5-dichlorophenyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenyl-methanone	20
(3-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	20
(4-fluorophenyl)[7-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	17
(2-chlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	24
(4-fluorophenyl)[5-methyl-7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	25
(4-fluorophenyl)[7-(2-fluorophenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	22
4-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile	10
[5-methyl-7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	27

TABLE III (continued)

Compound	% Inhibition
(6-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl)phenyl-methanone	56
(6-methyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)phenyl-methanone	24
3-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone	77
(3,4-dimethoxyphenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	75
(3,4-dimethoxyphenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	94
(3-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	70
(3,5-dimethoxyphenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	30
(3-methylphenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	67
(3-methylphenyl)[7-(3-methylphenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	75
(4-chlorophenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	81
(4-chlorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	87
(4-chlorophenyl)[7-(4-fluorophenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	16

TABLE III (continued)

	Compound	% Inhibition
5	(3-fluorophenyl)[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	96
10	[5-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone, pyridine-1-oxide	52
15	(3-fluorophenyl)[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	52
20	[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-pyridinyl-methanone	64
25	(4-fluorophenyl)[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	34
30	N-[3-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide	65
35	N-[4-(3-benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide	33

The sedative-hypnotic properties of the novel compounds of the instant invention have been established by their effect on the duration of ethanol induced narcosis in rats as a measurement of sedation. Groups of at least 8 rats were administered graded oral doses of the test compounds or vehicle 60 minutes prior to intraperitoneal treatment with 3.2 g/kg ethanol. Rats were then observed continuously for 180 minutes for the incidence and duration of ethanol induced narcosis. A rat was considered to exhibit narcosis if it remained in a supine position on a horizontal surface for at least 1 minute; the end of narcosis was defined as the rat spontaneously righting itself and remaining righted for at least 1 minute. The duration of narcosis was the total time the rat remained in a supine position. The MED [lowest dose necessary to cause a significant ($p \leq 0.05$, two-tailed Student's t test) increase in the duration of ethanol induced narcosis in rats] of representative compounds of this invention are shown in Table IV. Test compounds were dissolved or suspended in a 2% aqueous starch suspension containing 5% polyethyleneglycol 400 and a drop of Tween[®] 80; ethanol (95%) was adjusted to final concentration (V:V) with 0.85% saline. All treatments were administered in a constant volume of 5 ml/kg.

55

60

65

TABLE IV

Effects on the Duration of Ethanol Induced Narcosis in Rats

Compound	MED (mg/kg)
phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	16
(4-fluorophenyl)[7-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	6
phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	8
2-furanyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	32
2-furanyl[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl]-methanone	32
(2-chlorophenyl)[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	4

40 The novel compounds of this invention have also been shown to have skeletal muscle relaxant activity by two tests. The first test measures the effect of representative compounds on the ability of rats to remain on an inclined screen. Groups of at least 6 rats were treated orally with graded doses of test compounds or vehicle and placed on a wire mesh screen (inclined at an angle of 60° from a horizontal level) 65 minutes later. The number of rats falling off the screen within 30 minutes was recorded. The ED₅₀ (dose necessary to cause 50% of the animals tested to fall off) was calculated according to the linear arc-sine transformation method of Finney, D. J. Statistical Methods in Biological Assay, 2nd Ed., Hafner, N. Y., 1964, pp. 454 ff. 45 Compounds were dissolved or suspended in a 2% aqueous starch suspension containing 5% polyethylene glycol 400 and a drop of polysorbate 80, and administered in a constant volume of 5 ml/kg. The results of 50 representative compounds of this invention appear in Table V.

TABLE V

Effect on Ability of Rats to Remain
on an Inclined Screen

10	Compound	ED50 (mg/kg)
15	phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	68.5
20	(4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	98
25	phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	9.9
30	phenyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	5.5
35	2-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	167
40	(4-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	11.1
45	2-pyridinyl[7-[3-(trifluoromethyl)-phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	6.9
50	(4-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	11.9

The second test to illustrate that the novel compounds of the present invention possess skeletal muscle relaxant properties is the effect of representative compounds on the locomotor activity in rats. Groups of 6 rats were treated orally with vehicle (5 ml/kg) or graded doses of the test compounds. Sixty minutes later, individual rats were placed in Actophotometers and locomotor activity was measured for 5 minutes after a brief (30 sec.) habituation period. Motor Activity Counts (number of crossings of the photo cells) were recorded for each rat, and mean activity counts were calculated for each treatment group. The dose causing a 50% decrease in mean activity counts compared with the vehicle group (MDD_{50}) was calculated from a linear regression equation. The test results of representative compounds appear in Table VI.

TABLE VI

Effects on Locomotor Activity in Rats

	Compound	MDD ₅₀ (mg/kg P.O.)
5	phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	51.4
10	(4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	48.9
15	phenyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	21.2
20	phenyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	5.5
25	2-furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]-methanone	500
30	(4-methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	13.2
35	2-pyridinyl[7-[3-(trifluoromethyl)phenyl]-pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	7.0
40	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	100.6
45	(4-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone	10.5

The novel compounds of the present invention have been found to be highly useful for drug therapy in mammals when administered in amounts ranging from about 0.1 mg to about 20.0 mg/kg of body weight per day. A preferred dosage regimen for optimum results would be from about 0.5 mg to about 10.0 mg/kg of body weight per day. Such dosage units are employed that a total of from about 10 to about 700 mg of active compound for a subject of about 70 kg of body weight are administered in a 24 hour period. This dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The compounds of this invention are preferably administered orally but may be administered in any convenient manner such as by the intravenous, intramuscular, or subcutaneous routes.

Compositions according to the present invention having the desired clarity, stability and adaptability for parenteral use are obtained by dissolving from 0.10% to 10.0% by weight of active compound in a vehicle consisting of a polyhydric aliphatic alcohol or mixtures thereof. Especially satisfactory are glycerin, propylene glycol, and polyethylene glycols. The polyethylene glycols consist of a mixture of nonvolatile, normally liquid, polyethylene glycols which are soluble in both water and organic liquids and which have molecular weight of from about 200 to 1500. Although the amount of active compound dissolved in the above vehicle may vary from 0.10% to 10.0% by weight, it is preferred that the amount of active compound employed be from about 3.0 to about 9.0% by weight. Although various mixtures of the aforementioned nonvolatile polyethylene glycols may be employed, it is preferred to use a mixture having an average

EP 0 129 847 B1

molecular weight of from about 200 to about 400.

In addition to the active compound, the parenteral solutions may also contain various preservatives which may be used to prevent bacterial and fungal contamination. The preservatives which may be used for these purposes are, for example, myristyl-gamma-picolinium chloride, benzalkonium chloride, phenethyl alcohol, *p*-chlorophenyl- α -glycerol ether, methyl and propyl parabens, and thimerosal. As a practical matter, it is also convenient to employ antioxidants. Suitable antioxidants include, for example, sodium bisulfite, sodium metabisulfite, and sodium formaldehyde sulfoxylate. Generally, from about 0.05 to about 0.2% concentrations of antioxidant are employed.

For intramuscular injection, the preferred concentration of active compound is 0.25 to 0.50 mg/ml of the finished compositions. The novel compounds of the present invention are equally adapted to intravenous administration when diluted with water or diluents employed in intravenous therapy such as isotonic glucose in appropriate quantities. For intravenous use, initial concentrations down to about 0.05 to 0.25 mg/ml of active ingredient are satisfactory.

The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Additionally, the active ingredient may be incorporated with the proper pharmaceutical carrier or carriers known in the art to produce a sustained-release tablet or capsule. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and the like may also contain one or more of the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a wetting agent such as sodium lauryl sulfate and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially nontoxic in the amounts employed.

The following non-limiting examples illustrate the preparation of representative compounds of the present invention.

Example 1

40 Phenyl[7-(3-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

A reaction mixture of 1.87 g of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone and 1.76 g of 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one in 25 ml of glacial acetic acid was refluxed for 6 hours and then the solvent was removed *in vacuo* giving a crystalline residue. This residue was partitioned between saturated aqueous sodium bicarbonate and methylene chloride. The organic layer was dried with anhydrous sodium sulfate and then passed through a short pad of hydrous magnesium silicate. The addition of hexane to the refluxing eluate induced crystallization. After cooling, the desired product was collected, giving 2.45 g, mp 202–203°C.

Following the general procedure of Example 1 and using appropriate substituted pyrazole derivatives and either appropriate substituted 3-dimethyl-1-(aryl)-2-propen(buten)-1-ones or in certain instances other aldehydes or ketones, the products of Examples 2–131, listed in Table VII, were obtained.

TABLE VII

Ex.	Pyrazole	Product	MPOC	
2	(3-amino-1H-pyrazol-4- y1)(4-fluorophenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- -1-one	(4-fluorophenyl)[7-(4-pyri- diny1)pyrazolo[1,5-a]pyrimi- din-3-y1]methanone	214-216
3	(3-amino-1H-pyrazol-4- y1)phenyl-methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- -1-one	phenyl[7-(4-pyridinyl)pyra- zolo[1,5-a]pyrimidin-3-y1] methanone	185-186
4	(3-amino-1H-pyrazol-4- y1)phenyl-methanone	3-dimethylamino-1- (phenyl)-2-propen-1- one	phenyl(7-phenylpyrazolo- [1,5-a]pyrimidin-3-y1) methanone	163-165
5	(3-amino-1H-pyrazol-4- y1)phenyl-methanone	3-dimethylamino-1-[3- (trifluoromethyl)- phenyl]-2-propen-1-one	phenyl[7-(3-(trifluorometh- yl)phenyl)pyrazolo[1,5-a]- pyrimidin-3-y1]methanone	148-150
6	(3-amino-1H-pyrazol-4- y1)(4-fluorophenyl)- methanone	3-dimethylamino-1-[3- (trifluoromethyl)- phenyl]-2-propen-1-one	(4-fluorophenyl)[7-[3-(tri- fluoromethyl)phenyl]pyrazolo- [1,5-a]pyrimidin-3-y1]metha- none	176-177
7	(3-amino-1H-pyrazol-4- y1)(4-fluorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen- -1-one	(4-fluorophenyl)[7-(3-pyri- diny1)pyrazolo[1,5-a]pyrimi- din-3-y1]methanone	235-236

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
8	(3-amino-1H-pyrazol-4-yl)(4-fluorophenyl)-methanone	3-dimethylamino-1-(phenyl)-2-propen-1-one	(4-fluorophenyl)(7-phenyl-3-pyrazolo[1,5-a]pyrimidin-3-yl)methanone	166-168
9	(3-amino-1H-pyrazol-4-yl)(4-fluorophenyl)-methanone	1-(3,4-dimethoxyphenyl)-3-dimethylamino-2-buten-1-one	[7-(3,4-dimethoxyphenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl](4-fluorophenyl)methanone	197-199
10	(3-amino-1H-pyrazol-4-yl)[3-(trifluoromethyl)phenyl]methanone	3-dimethylamino-1-[3-(trifluoromethyl)phenyl]-2-propen-1-one	[3-(trifluoromethyl)phenyl][7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl)methanone	157-159
11	(3-amino-1H-pyrazol-4-yl)[3-(trifluoromethyl)phenyl]methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]trifluoromethylphenyl)methanone	221-222
12	(3-amino-1H-pyrazol-4-yl)phenylmethanone	3-dimethylamino-1-(3-pyridinyl)-2-buten-1-one	[5-methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenylmethanone	196-198

TABLE VII (continued)

Ex.	Pyrazole	Product	Mpoc
13	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-Dimethylamino-1-(aryl)-2-propen-1-one	
14	(3-amino-1H-pyrazol-4-yl)-2-thienyl-methanone	3-dimethylamino-1-[3-(trifluoromethyl)phenyl]-2-propen-1-one	2-thienyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
15	(3-amino-1H-pyrazol-4-yl)-2-furanyl-methanone	3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one	2-furanyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
16	(3-amino-1H-pyrazol-4-yl){3-(trifluoromethyl)phenyl}methanone	3-dimethylamino-1-(phenyl)-2-propen-1-one	(7-phenyl)pyrazolo[1,5-a]pyrimidin-3-yl[3-(trifluoromethyl)phenyl]methanone
17	(3-amino-1H-pyrazol-4-yl)-2-thienyl-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]2-thienyl-methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPC
18	(3-amino-1H-pyrazol-4- y1)-2-(trifluoromethyl)- phenyl)methanone	3-dimethylamino-1-(2- furanyl)-2-propen-1- one	[7-(2-furanyl)pyrazolo- [1,5-a]pyrimidin-3-y1]- (trifluoromethyl)phenyl]- methanone
19	(3-amino-1H-pyrazol-4- y1)-2-furanyl-methanone	3-dimethylamino-1-(3- (trifluoromethyl)- phenyl)-2-propen-1- one	2-furanyl[7-[3-(trifluoro- methyl)phenyl]pyrazolo[1,5-]- pyrimidin-3-y1]methanone
20	(3-amino-1H-pyrazol-4- y1)-2-furanyl-methanone	3-dimethylamino-1-(3- pyridiny1)-2-propen-1- one	2-furanyl[7-(3-pyridiny1)- pyrazolo[1,5-a]pyrimidin-3- y1]methanone
21	(3-amino-1H-pyrazol-4- y1)-2-furanyl-methanone	3-dimethylamino-1-(2- fluorophenyl)-2-propen-1- one	[7-(2-fluorophenyl)pyrazolo- [1,5-a]pyrimidin-3-y1]-2- furanyl-methanone
22	(3-amino-1H-pyrazol-4- y1)-2-furanyl-methanone	3-dimethylamino-1- (phenyl)-2-propen-1- one	2-furanyl(7-phenylpyrazolo- [1,5-a]pyrimidin-3-y1]- methanone
23	(3-amino-5-methyl-1H- pyrazol-4-y1)phenyl- methanone	3-dimethylamino-1-(3- pyridyl)-2-propen-1- one	[2-methyl-7-(3-pyridiny1)- pyrazolo[1,5-a]pyrimidin-3- y1]phenyl-methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC	
24	(3-amino-1H-pyrazol-4- y1) [3-(trifluoromethyl)- phenyl]methanone	3-dimethylamino-1- (ary1)-2-propen-1-one 3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	[7-(4-pyridinyl)pyrazolo- [1,5-a]pyrimidin-3-y1] [3- (trifluoromethyl)phenyl] methanone	207-208
25	(3-amino-1H-pyrazol-4- y1)-4-pyridinyl-metha- none	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	4-pyridinyl [7-(4-pyridinyl)- pyrazolo[1,5-a]pyrimidin-3- y1]methanone	260-262
26	(3-amino-5-methyl-1H- pyrazol-4-y1)phenyl- methanone	3-dimethylamino-1-(3- (trifluoromethyl)- phenyl)-2-propen-1-one	(2-methyl-7-[3-(trifluoro- methy1)phenyl]pyrazolo- [1,5-a]pyrimidin-3-y1)phenyl- methanone	156-158
27	(3-amino-1H-pyrazol-4- y1)-2-thienyl-methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	7-(4-pyridinyl)pyrazolo- [1,5-a]pyrimidin-3-y1)-2- thienyl-methanone	248-249
28	(3-amino-1H-pyrazol-4- y1) [3-(trifluoromethyl)- phenyl]methanone	3-dimethylamino-1-(3- chlorophenyl)-2-propen-1-one	[7-(3-chlorophenyl)pyrazolo- [1,5-a]pyrimidin-3-y1] [3- (trifluoromethyl)phenyl]- methanone	178-180

TABLE VII (continued)

Ex.	Pyrazole	Product	Mp°C
29	(3-amino-1H-pyrazol-4- y1) phenyl-methanone	3-Dimethylamino-1- (ary1)-2-propen-1-one	phenyl[7-(2-thieny1)pyrazolo- [1,5-a]pyrimidin-3-y1]metha- none
30	(3-amino-1H-pyrazol-4- y1) phenyl-methanone	3-dimethylamino-1-(2- pyridinyl)-2-propen-1- one	phenyl[7-(2-pyridinyl)pyra- zolo[1,5-a]pyrimidin-3-y1]- methanone
31	(3-amino-1H-pyrazol-4- y1) phenyl-methanone	3-dimethylamino-1-(3- chlorophenyl)-2-propen-1- one	[7-(3-chlorophenyl)pyrazolo- [1,5-a]pyrimidin-3-y1]phenyl- methanone
32	(3-amino-1H-pyrazol-4- y1) phenyl-methanone	3-dimethylamino-1-(4- pyridinyl)-2-buten-1- one	[5-methyl-7-(4-pyridinyl)- pyrazolo[1,5-a]pyrimidin-3- y1]phenyl-methanone
33	(3-amino-1H-pyrazol-4- y1) phenyl-methanone	3-dimethylamino-1-(2- chloro-5-(trifluoro- methyl)phenyl)-2-propen-1- one	[7-(2-chloro-5-(trifluoro- methyl)phenyl)pyrazolo- [1,5-a]pyrimidin-3-y1]phenyl- methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
34	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(3-fluorophenyl)-2-propen-1-one	[7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone 199-201
35	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(3-thienyl)-2-propen-1-one	phenyl[7-(3-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone 150-152
36	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-[3-(methylthio)phenyl]-2-propen-1-one	[7-(3-(methylthio)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone 126-127
37	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	1-(3,4-dichlorophenyl)-3-(dimethylamino)-2-but en-1-one	(7-(3,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)phenyl-methanone 194-196
38	(3-amino-1H-pyrazol-4-yl)(4-methylphenyl)-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(4-methylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone 203-204

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
39	(3-amino-1 <i>H</i> -pyrazol-4- <i>Y</i> 1) (4-methylphenyl) - methanone	3-dimethylamino-1-(2- pyridinyl)-2-propen-1- one	(4-methylphenyl)[7-(2-pyr1- diny1)pyrazolo[1,5- <u>a</u>]pyrimi- din-3- <u>Y</u> 1]methanone 188-189
40	(3-amino-1 <i>H</i> -pyrazol-4- <i>Y</i> 1) (4-methylphenyl) - methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	(4-methylphenyl)[7-(4-pyr1- diny1)pyrazolo[1,5- <u>a</u>]pyrimi- din-3- <u>Y</u> 1]methanone 196-197
41	(3-amino-1 <i>H</i> -pyrazol-4- <i>Y</i> 1) (4-methylphenyl) - methanone	3-dimethylamino-1-(3- (trifluoromethyl)- phenyl)-2-propen-1-one	(4-methylphenyl)[7-(3-(trifluoromethyl)phenyl)pyrazolo[1,5- <u>a</u>]pyrimidin-3- <u>Y</u> 1]- methanone 158-159
42	(3-amino-1 <i>H</i> -pyrazol-4- <i>Y</i> 1) (4-methylphenyl) - methanone	3-dimethylamino-1-(3- thienyl)-2-propen-1- one	(4-methylphenyl)[7-(3-thienyl)pyrazolo[1,5- <u>a</u>]pyrimidin-3- <u>Y</u> 1]methanone 168-169
43	(3-amino-1 <i>H</i> -pyrazol-4- <i>Y</i> 1)-2-pyridinyl-metha- none	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	2-pyridinyl[7-(3-pyridinyl)- pyrazolo[1,5- <u>a</u>]pyrimidin-3- <u>Y</u> 1]methanone 216-218

TABLE VII (continued)

Ex.	Pyrazole	Product	MpOC
44	3-amino-1H-pyrazol-4- y1)-2-pyridinyl-metha- none	3-dimethylamino-1- (aryl)-2-propen-1-one	2-pyridinyl[7-(2-pyridinyl)- pyrazolo[1,5-a]pyrimidin-3- yl]methanone
45	(3-amino-1H-pyrazol-4- y1)-2-pyridinyl-metha- none	3-dimethylamino-1-(3- (trifluoromethyl)phenyl)- 2-propen-1-one	2-pyridinyl[7-[3-(trifluoro- methyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]metha- none
46	(3-amino-1H-pyrazol-4- y1)-2-pyridinyl-metha- none	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	2-pyridinyl[7-(4-pyridinyl)- pyrazolo[1,5-a]pyrimidin-3- yl]methanone
47	(3-amino-1H-pyrazol-4- y1)-3-fluorophenyl- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	(3-fluorophenyl)[7-(4-pyri- dinyl)pyrazolo[1,5-a]pyrimi- din-3-yl]methanone
48	(3-amino-1H-pyrazol-4- y1)-2-pyridinyl-metha- none	3-dimethylamino-1-(2- thienyl)-2-propen-1- one	2-pyridinyl[7-(2-thienyl)- pyrazolo[1,5-a]pyrimidin-3- yl]methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	Mp°C	
49	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(2,5-dichlorophenyl)-2-propen-1-one	[7-(2,5-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	194-195
50	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(4-fluorophenyl)-2-propen-1-one	[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	187-188
51	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(3,5-dichlorophenyl)-2-propen-1-one	[7-(3,5-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	206-208
52	(3-amino-1H-pyrazol-4-yl)-3-fluorophenyl-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(3-fluorophenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	185-186
53	(3-amino-1H-pyrazol-4-yl)(4-fluorophenyl)-methanone	3-dimethylamino-1-(2-pyridinyl)-2-propen-1-one	(4-fluorophenyl)[7-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	213-215

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
54	(3-amino-1H-pyrazol-4- Y1) (2-chlorophenyl)- methanone	3-dimethylamino-1-(ary1)-2-propen-1-one	143-144
55	(3-amino-1H-pyrazol-4- Y1) (4-fluorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen-1- one	256-257
56	(3-amino-1H-pyrazol-4- Y1) (4-fluorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-buten-1- one	176-177
57	(3-amino-1H-pyrazol-4- Y1) (4-fluorophenyl)- methanone	3-dimethylamino-1-(2- fluorophenyl)-2-propen-1- one	189-190
58	(3-amino-1H-pyrazol-4- Y1) (4-fluorophenyl)- methanone	3-dimethylamino-1-[4-(trifluoromethyl)phenen- yl]-2-propen-1-one	187-188

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
59	(3-amino-1H-pyrazol-4-yl)(4-fluorophenyl)-methanone	3-dimethylamino-1-(4-cyanophenyl)-2-propen-1-one	4-[3-(4-fluorobenzoyl)pyrazolo[1,5-a]pyrimidin-7-yl]-benzonitrile	264-266
60	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-(4-cyanophenyl)-2-propen-1-one	4-(3-benzoylepyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile	210-212
61	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-[3-(trifluoromethyl)-phenyl]-2-buten-1-one	[5-methyl-7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-phenyl-methanone	153-154
62	(3-amino-1H-pyrazol-4-yl)(3,4,5-trimethoxy-phenyl)methanone	3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one	[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-[3,4,5-trimethoxyphenyl]-methanone	210-211
63	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-2-methyl-1-(4-pyridinyl)-2-propen-1-one	[6-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone	210-211

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
64	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-2-methyl-1-phenyl-2-propen-1-one	(6-methyl-7-phenylpyrazolo-[1,5-a]pyrimidin-3-yl)phenyl-methanone	218-220
65	(3-amino-1H-pyrazol-4-yl)-3-furanyl-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	3-furanyl[7-(3-pyridinyl)-pyrazolo[1,5-a]pyrimidin-3-yl]methanone	236-238
66	(3-amino-1H-pyrazol-4-yl)(3',4',5'-trimethoxyphenyl)methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	[7-(3-pyridinyl)pyrazolo-[1,5-a]pyrimidin-3-yl](3,4,5-trimethoxyphenyl)methanone	236-237
67	(3-amino-1H-pyrazol-4-yl)(3',4',5'-trimethoxyphenyl)methanone	3-dimethylamino-1-(trifluoromethyl)-2-propen-1-one	[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl](3,4,5-trimethoxyphenyl)methanone	203-204
68	(3-amino-1H-pyrazol-4-yl)(3,4-dimethoxyphenyl)methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(3,4-dimethoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	210-211

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
69	(3-amino-1H-pyrazol-4-yl) (3,4-dimethoxyphenyl) methanone	3-dimethylamino-1-[3-(trifluoromethyl)-phenyl]-2-propen-1-one	(3,4-dimethoxyphenyl) [7-(3-(trifluoromethyl)phenyl) pyrazolo[1,5-a]pyrimidin-3-yl]methanone	186-187
70	(3-amino-1H-pyrazol-4-yl) (3,4-dimethoxyphenyl) methanone	3-dimethylamino-1-(3,4,5-trimethoxyphenyl)-2-propen-1-one	(3,4-dimethoxyphenyl) [7-(3,4,5-trimethoxyphenyl) pyrazolo[1,5-a]pyrimidin-3-yl]methanone	215-216
71	(3-amino-1H-pyrazol-4-yl) (3-methylphenyl) methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(3-methylphenyl) [7-(3-pyridinyl) pyrazolo[1,5-a]pyrimidin-3-yl]methanone	156-158
72	(3-amino-1H-pyrazol-4-yl) (3,5-dimethoxyphenyl) methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(3,5-dimethoxyphenyl) [7-(3-pyridinyl) pyrazolo[1,5-a]pyrimidin-3-yl]methanone	207-208
73	(3-amino-1H-pyrazol-4-yl) (3,4-dimethoxyphenyl) methanone	3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one	(3,4-dimethoxyphenyl) [7-(4-pyridinyl) pyrazolo[1,5-a]pyrimidin-3-yl]methanone	232-234

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
74	(3-amino-1H-pyrazol-4-yl)(3-methylphenyl)-methanone	3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one	(3-methylphenyl)[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	163-165
75	(3-amino-1H-pyrazol-4-yl)(3-methylphenyl)-methanone	3-dimethylamino-1-[3-(trifluoromethyl)-phenyl]-2-propen-1-one	(3-methylphenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	163-164
76	(3-amino-1H-pyrazol-4-yl)(3-methylphenyl)-methanone	3-dimethylamino-1-(3-methylphenyl)-2-propen-1-one	(3-methylphenyl)[7-(3-methylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	111-113
77	(3-amino-1H-pyrazol-4-yl)(4-chlorophenyl)-methanone	3-dimethylamino-1-(3-(trifluoromethyl)-phenyl)-2-propen-1-one	(4-chlorophenyl)[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	183-185
78	(3-amino-1H-pyrazol-4-yl)phenyl-methanone	3-dimethylamino-1-phenyl-2-buten-1-one	(5-methyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)phenylmethanone	165-166

TABLE VII (continued).

Ex.	Pyrazole	Product	MP°C	
79	(3-amino-1H-pyrazol-4- yl) (4-chlorophenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1- one	(4-chlorophenyl)[7-(4-pyri- diny1)pyrazolo[1,5- <u>a</u>]pyrimi- din-3-yl]methanone	250-252
80	(3-amino-1H-pyrazol-4- yl) (4-chlorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	(4-chlorophenyl)[7-(3-pyri- diny1)pyrazolo[1,5- <u>a</u>]pyrimi- din-3-yl]methanone	255-256
81	(3-amino-1H-pyrazol-4- yl) (4-chlorophenyl)- methanone	1-[3-(trifluorometh- yl)phenyl]-3-dimethyl- amino-2-buten-1-one	(4-chlorophenyl)[5-methyl-7- [3-(trifluoromethyl)phenyl]- pyrazolo[1,5- <u>a</u>]pyrimidin-3- yl]methanone	218-220
82	(3-amino-1H-pyrazol-4- yl) (4-chlorophenyl)- methanone	3-dimethylamino-1-(4- fluorophenyl)-2-pro- pen-1-one	(4-chlorophenyl)[7-(4-fluoro- phenyl)pyrazolo[1,5- <u>a</u>]- pyrimidin-3-yl]methanone	258-260
83	(3-amino-1H-pyrazol-4- yl) (3-fluorophenyl)- methanone	3-dimethylamino-1-(3- (trifluoromethyl)- phenyl)-2-propen-1-one	(3-fluorophenyl)[7-[3-(tri- fluoromethyl)phenyl]pyrazolo- [1,5- <u>a</u>]pyrimidin-3-yl]metha- none	164-165

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
84	(3-amino-1H-pyrazol-4-yl) (3-fluorophenyl)-methanone	(3-dimethylamino-1-(4-dimethylamino-1-(4-fluorophenyl)-2-propen-1-one)-2-propen-1-one	202-203
85	(3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone	(3-dimethylamino-1-(4-fluorophenyl)-2-propen-1-one)-2-propen-1-one	213-214
86	(3-amino-1H-pyrazol-4-yl) (4-fluorophenyl)-methanone	(3-dimethylamino-1-(4-fluorophenyl)-2-propen-1-one)-2-propen-1-one	224-225
87	(3-amino-1H-pyrazol-4-yl) (4-methoxyphenyl)-methanone	(3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one)-2-propen-1-one	193-195
88	(3-amino-1H-pyrazol-4-yl) (4-fluorophenyl)-methanone	(3-dimethylamino-1-(4-pyridinyl)-2-buten-1-one)-2-buten-1-one	256-258

TABLE VII (continued)

Ex.	Pyrazole	3-Dimethylamino-1-(aryl)-2-propen-1-one	Product	MPOC
89	(3-amino-1H-pyrazol-4- y1)[3-(trifluoromethyl- yl)phenyl]methanone	3-dimethylamino-1-(4- fluorophenyl)-2-propen- 1-one	[7-(4-fluorophenyl)pyrazolo- [1,5-a]pyrimidin-3-yl][3-(trifluoromethyl)phenyl]methanone	193-194
90	(3-amino-1H-pyrazol-4- y1)(4-methoxyphenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- 1-one	(4-methoxyphenyl)[7-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3- y1]methanone	235-236
91	(3-amino-1H-pyrazol-4- y1)(3-methoxyphenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- 1-one	(3-methoxyphenyl)[7-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3- y1]methanone	144-146
92	(3-amino-1H-pyrazol-4- y1)(3-methoxyphenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	(3-methoxyphenyl)[7-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3- y1]methanone	166-168
93	(3-amino-1H-pyrazol-4- y1)[4-(trifluoromethyl- yl)phenyl]methanone	3-dimethylamino-1-[4-(trifluoromethyl)phenyl]- 2-propen-1-one	[4-(trifluoromethyl)phenyl][7-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	Syrup

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
94	(3-amino-1H-pyrazol-4- y1)(3-chlorophenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- 1-one	(3-chlorophenyl)[7-(4-pyridin- y1)pyrazolo[1,5-a]pyrimidin-3- y1]methanone 196-198
95	(3-amino-1H-pyrazol-4- y1)(3-chlorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	(3-chlorophenyl)[7-(3-pyridin- y1)pyrazolo[1,5-a]pyrimidin-3- y1]methanone syrup
96	(3-amino-1H-pyrazol-4- y1)[4-(trifluorometh- y1)phenyl]methanone	3-dimethylamino-1-((3,4-dichlorophenyl)- 2-propen-1-one	[7-(3,4-dichlorophenyl)pyra- zolo[1,5-a]pyrimidin-3-y1][4- (trifluoromethyl)phenyl] methanone 170-172
97	(3-amino-1H-pyrazol-4- y1)(4-fluorophenyl)- methanone	3-dimethylamino-2- methyl-1-(3-pyridin- y1)-2-propen-1-one	(4-fluorophenyl)[6-methyl-7-(3- pyridinyl)pyrazolo[1,5-a]pyrim- idin-3-y1]methanone 182-183
98	(3-amino-1H-pyrazol-4- y1)(3-chlorophenyl)- methanone	3-dimethylamino-1-(4- fluorophenyl)-2- propen-1-one	(3-chlorophenyl)[7-(4-fluoro- phenyl)pyrazolo[1,5-a]pyrimi- din-3-y1]methanone 198-200

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
99	(3-amino-1H-pyrazol-4- y1)(2,5-dichlorophen- y1)methanone	3-dimethylamino-1-(4- fluorophenyl)-2-propen-1-one	(2,5-dichlorophenyl)[7-(4- fluorophenyl)pyrazolo[1,5-a]- pyrimidin-3-y1]methanone
100	(3-amino-1H-pyrazol-4- y1)(2,5-dichlorophen- y1)methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen-1-one	(2,5-dichlorophenyl)[7-(3-pyri- diny1)pyrazolo[1,5-a]pyrimidin- 3-y1]methanone
101	(3-amino-1H-pyrazol-4- y1)(2,5-dichlorophen- y1)methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1-one	(2,5-dichlorophenyl)[7-(4-pyri- diny1)pyrazolo[1,5-a]pyrimidin- 3-y1]methanone
102	(3-amino-1H-pyrazol-4- y1)phenylmethanone	3-dimethylamino-1-[4- (methylthio)phenyl]- 2-propen-1-one	[7-[4-(methylthio)phenyl]pyra- zolo[1,5-a]pyrimidin-3-y1]- phenylmethanone
103	(3-amino-1H-pyrazol-4- y1)(2-methylphenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen-1-one	(2-methylphenyl)[7-(3-pyridin- y1)pyrazolo[1,5-a]pyrimidin-3- y1]methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPC
104	(3-amino-1H-pyrazol-4- y1)(2-methylphenyl)- methanone	3-dimethylamino-1-(ary1)-2-propen-1-one	(2-methylphenyl)[7-(4-pyridin- y1)pyrazolo[1,5-a]pyrimidin-3- y1]methanone
105	(3-amino-1H-pyrazol-4- y1)(2-chlorophenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- 1-one	(2-chlorophenyl)[7-(4-pyridin- y1)pyrazolo[1,5-a]pyrimidin-3- y1]methanone
106	(3-amino-1H-pyrazol-4- y1)(2-methylphenyl)- methanone	3-dimethylamino-1-(4- (trifluoromethyl)- phenyl)-2-propen-1-one	(2-methylphenyl)[7-(4-tri- fluoromethyl)phenyl]pyrazolo- [1,5-a]pyrimidin-3-y1]methanone
107	(3-amino-1H-pyrazol-4- y1)-4-pyridinylmetha- none	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	4-pyridinyl[7-(3-pyridinyl)- pyrazolo[1,5-a]pyrimidin-3-y1]- methanone
108	(3-amino-1H-pyrazol-4- y1)-4-pyridinylmetha- none	3-dimethylamino-1-(3- (trifluoromethyl)phen- yl)-2-propen-1-one	4-pyridinyl[7-[3-trifluoro- methyl)phenyl]pyrazolo[1,5-a]- pyrimidin-3-y1]methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
109	(3-amino-1H-pyrazol-4- y1)-4-pyridinylmetha- none	3-dimethylamino-1-(4- fluorophenyl)-2-propen-1-one	[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-y1]-4-pyri- dinylmethanone
110	(3-amino-1H-pyrazol-4- y1)-2-pyridinylmetha- none	3-dimethylamino-1-[4-(trifluoromethyl)- phenyl]-2-propen-1-one	2-pyridinyl[7-[4-(trifluoro- methyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-y1]methanone
111	(3-amino-1H-pyrazol-4- y1)[4-(dimethylamino)- phenyl]methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen-1-one	[4-(dimethylamino)phenyl][7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-y1]methanone
112	(3-amino-1H-pyrazol-4- y1)[4-(dimethylamino)- phenyl]methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen-1-one	[4-(dimethylamino)phenyl][7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-y1]methanone
113	(3-amino-1H-pyrazol-4- y1)[4-(dimethylamino)- phenyl]methanone	3-dimethylamino-1-[3-(trifluoromethyl)- phenyl]-2-propen-1-one	[4-(dimethylamino)phenyl][7-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-y1]me- thanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
	3-Dimethylamino-1-(aryl)-2-propen-1-one		
114	(3-amino-5-methyl-1H-pyrazol-4-yl)phenylmethanone	[2-methyl-7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	178-180
115	(3-amino-1H-pyrazol-4-yl)phenylmethanone	[6-methyl-1-[3-(trifluoromethyl)phenyl]-2-propen-1-one]	174-175
116	(3-amino-1H-pyrazol-4-yl)(2-methoxyphenyl)methanone	[2-methoxyphenyl]-7-[3-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	144-145
117	(3-amino-1H-pyrazol-4-yl)[3,4-(methylenedioxy)phenyl]methanone	[1,3-benzodioxol-5-yl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	212-213
118	(3-amino-1H-pyrazol-4-yl)[3,4-methylenedioxy)phenyl]methanone	[1,3-benzodioxol-5-yl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone	236-237

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
119	(3-amino-1H-pyrazol-4-yl)(4-ethoxyphenyl)-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(4-ethoxyphenyl)[7-(3-pyridin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
120	(3-amino-1H-pyrazol-4-yl)-2-naphthalenyl-methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	2-naphthalenyl[7-(3-pyridin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
121	(3-amino-1H-pyrazol-4-yl)-2-thienylmethanone	3-dimethylamino-1-[4-(trifluoromethyl)-phenyl]-2-propen-1-one	2-thienyl[7-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
122	(3-amino-1H-pyrazol-4-yl)-2-thienylmethanone	3-dimethylamino-1-(3-fluorophenyl)-2-propen-1-one	[7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-thienylmethanone
123	(3-amino-1H-pyrazol-4-yl)(2-methoxyphenyl)-methanone	3-dimethylamino-1-(4-fluorophenyl)-2-propen-1-one	[7-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-3-yl](2-methoxyphenyl)methanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
124	(3-amino-1H-pyrazol-4-yl)(5-methyl-2-thienyl)methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(5-methyl-2-thienyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
125	(3-amino-1H-pyrazol-4-yl)-3-thienylmethanone	3-dimethylamino-1-[3-(trifluoromethyl)phenyl]-2-propen-1-one	3-thienyl[7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone
126	(3-amino-1H-pyrazol-4-yl)-3-thienylmethanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-3-thienylmethanone
127	(3-amino-1H-pyrazol-4-yl)(4-ethylphenyl)methanone	3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one	(4-ethylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
128	(3-amino-1H-pyrazol-4-yl)-3-thienylmethanone	3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one	[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-3-thienylmethanone

TABLE VII (continued)

Ex.	Pyrazole	Product	MPOC
129	(3-amino-1H-pyrazol-4- yl)(2-fluorophenyl)- methanone	3-dimethylamino-1-(4- pyridinyl)-2-propen- 1-one	(2-fluorophenyl)[7-(4-pyridin- yl)pyrazolo[1,5-a]pyrimidin-3- yl]methanone 188-189
130	(3-amino-1H-pyrazol-4- yl)(2-fluorophenyl)- methanone	3-dimethylamino-1-(3- pyridinyl)-2-propen- 1-one	(2-fluorophenyl)[7-(3-pyridin- yl)pyrazolo[1,5-a]pyrimidin-3- yl]methanone 164-165
131	(3-amino-1H-pyrazol-4- yl)(2-fluorophenyl)- methanone	3-dimethylamino-1-[3- (trifluoromethyl)- phenyl]-2-propen-1-one	(2-fluorophenyl)[7-[3-(tri- fluoromethyl)phenyl]pyrazolo- [1,5-a]pyrimidin-3-yl]methanone 155-157

EP 0 129 847 B1

Example 132

Phenyl[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone, pyridine-1-oxide

A 3.0 g portion of [7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone was dissolved in 200 ml of methylene chloride. A 2.0 g portion of 80—90% *m*-chloroperbenzoic acid was added and the mixture was stirred for 18 hours. The solid was collected, air dried, slurried in 50 ml of saturated aqueous sodium bicarbonate, added to 150 ml of water and heated to boiling. The solution was clarified while hot, then cooled. The solid was washed with water and air dried at 50°C, giving 0.4 g of the desired product, mp 239—244°C.

10

Example 133

(4-Fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone, pyridine-1-oxide

A 1.6 g portion of (4-fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone was reacted as described in Example 132, giving 1.0 g of the desired product, mp 283—285°C (dec.).

15

Example 134

[5-Methyl-7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]phenyl-methanone, pyridine-1-oxide

A 2.1 g portion of [5-methyl-7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]phenyl-methanone was reacted as described in Example 132, giving 1.8 g of the desired product, mp 249—250°C.

20

Example 135

Phenyl(7-phenylpyrazolo[1,5-*a*]pyrimidin-3-yl)methanone

A mixture of 0.01 mole of 3-chloro-3-phenyl-2-propenal and 0.01 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 25 ml of acetic acid was refluxed for 6 hours. The solvent was removed *in vacuo* and the product isolated as described in Example 1, giving the desired product as crystals, mp 163—165°C.

25

Example 136

2-Furanyl[7-(3-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

A mixture of 0.02 mole of 3-chloro-3-(3-pyridinyl)-2-propenal and 0.02 mole of (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone in 30 ml of glacial acetic acid was refluxed for 5 hours. The solvent was removed *in vacuo* and the residue partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was dried over sodium sulfate and passed through a short pad of hydrous magnesium silicate. The eluent was concentrated and the residue was crystallized from dichloromethane:hexane to give the desired product as crystals, mp 228—229°C.

35

Example 137

2-Furanyl[7-(3-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

A mixture of 0.1 mole of 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one and a 0.15 mole of pyrrolidine in 200 ml of xylene was refluxed with distillation of the xylene by passing a stream of argon through the solution. Additional xylene was added periodically. After 10 hours the solvent was removed to give crude 3-(1-pyrrolidinyl)-1-(3-pyridinyl)-2-propen-1-one. This crude compound and 0.1 mole of (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone in 100 ml of glacial acetic acid was refluxed for 8 hours. The solvent was removed *in vacuo* and the product isolated as described in Example 1, giving the desired product as crystals, mp 228—229°C.

45

Example 138

[5-Methyl-7-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]phenyl-methanone

A mixture of 0.05 mole of 1-[3-[3-(trifluoromethyl)phenyl]butan-1,3-dione and 0.05 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 40 ml of glacial acetic acid was refluxed for 10 hours. The solvent was removed *in vacuo* and the residue partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was dried over sodium sulfate and passed through a short pad of hydrous magnesium silicate. The eluent was concentrated and the residue was crystallized from dichloromethane:hexane to give the desired product as crystals, mp 153—154°C.

Example 139

55 [5-Methyl-7-phenylpyrazolo[1,5-*a*]pyrimidin-3-yl]phenyl-methanone

A mixture of 0.01 mole of 1-(3-phenyl)butan-1,3-dione and 0.01 mole of (3-amino-1*H*-pyrazol-4-yl)phenylmethanone in 25 ml of *n*-butanol was refluxed for 8 hours. The solvent was removed and the product isolated as described in Example 1, giving the desired product as crystals, mp 165—166°C.

60

Example 140

[5-Methyl-7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]phenyl-methanone

A mixture of 0.05 mole of 3-(1-pyrrolidinyl)-1-(4-pyridinyl)-2-buten-1-one and 0.05 ml of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 50 ml of glacial acetic acid was refluxed for 8 hours. The solvent was removed and the residue partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was washed with water, dried over magnesium sulfate and

EP 0 129 847 B1

passed through a short pad of hydrous magnesium silicate. The eluent was concentrated and the residue crystallized from dichloromethane:hexane, giving the desired product, mp 209—210°C.

Example 141

5 Phenyl[7-[(3-trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 100 ml of diethyl ether, 3.36 g of sodium hydride (60% in oil), 7.4 g of ethyl formate and 18.8 g of *m*-trifluoromethylacetophenone was refluxed with vigorous stirring for 2 hours, then cooled and the precipitate collected, giving 14.6 g of the sodium salt of 3-hydroxy-3-(trifluoromethyl)acrylophenone.

10 A suspension of 12.0 g of the above compound in 75 ml of dioxane and 10 ml of acetic anhydride was stirred at room temperature for 2 hours and then poured into water. The precipitate was collected, dissolved in dichloromethane and passed through a short pad of hydrous magnesium silicate. The eluent was concentrated and hexane added, giving 3-hydroxy-3'-(trifluoromethyl)acrylophenone acetate as

15 crystals, mp 55—57°C. A mixture of 0.03 mole of these crystals and 0.03 mole of 3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 30 ml of glacial acetic acid was refluxed for 5 hours. The solvent was removed and the residue partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was dried over magnesium sulfate and passed through a short pad of hydrous magnesium silicate. The eluent was concentrated and diluted with hexane, giving the desired product as crystals, mp 148—150°C.

20 Example 142

Phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 0.02 mole of 3-chloro-3-(3-pyridinyl)-2-propenal and 0.02 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 25 ml of glacial acetic acid was refluxed for 5 hours. The solvent was removed and the product isolated as described in Example 1, giving the desired product as crystals, mp 202—203°C.

25 Example 143

Phenyl(7-phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 3.2 g (0.02 mole) of 3-chloro-3-phenyl-2-propenal and 0.02 mole of 3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 25 ml of glacial acetic acid was refluxed for 6 hours. The solvent was removed and the product was isolated as described in Example 1, giving crystals, mp 163—165°C.

Example 144

[5-Methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone

35 A mixture of 8.16 g (0.05 mole) of 1-(3-pyridinyl)butan-1,3-dione and 0.05 mole of 3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 40 ml of glacial acetic acid was refluxed for 8 hours. The solvent was removed *in vacuo* and the product isolated as described in Example 1, giving the desired product as crystals, mp 196—198°C.

40 Example 145

[5-Methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone

A mixture of 8.16 g (0.05 mole) of 1-(3-pyridinyl)butan-1,3-dione and 0.05 mole of 3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in xylene was refluxed for 20 hours. The solvent was removed and the residue dissolved in dichloromethane. This solution was filtered, dried over magnesium sulfate and passed through a short pad of hydrous magnesium silicate. The eluent was concentrated with hexane added during concentration. Cooling and filtration gave the desired product as crystals, mp 196—198°C.

Example 146

[5-Methyl-7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone

50 To a solution of 16.32 g of 1-(3-pyridinyl)-butan-1,3-dione in 200 ml of ethyl acetate was added 7.11 g of pyrrolidine. The mixture was stirred at room temperature and then the crystals were collected giving 7.0 g of 3-(1-pyrrolidinyl)-1-(3-pyridinyl)-2-buten-1-one, mp 116—118°C.

A 0.02 mole portion of the above compound and 0.02 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 25 ml of glacial acetic acid was refluxed for 8 hours. The solvent was removed and the product isolated as described in Example 1, giving the desired product as crystals, mp 196—198°C.

55 Example 147

Phenyl[7-[(3-trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 0.10 mole of 3-dimethylamino-1-[(3-trifluoromethyl)phenyl]-2-propen-1-one and 0.10 mole of *p*-toluenesulfonic acid in 100 ml of ethanol was warmed at 60°C for 12 hours and the solvent removed *in vacuo*. The residue was partitioned between dichloromethane and water. The organic layer was dried over magnesium sulfate and concentrated, giving crude 3-ethoxy-1-[(3-trifluoromethyl)-phenyl]-2-propen-1-one.

60 A mixture of the above compound and 0.10 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone in 75 ml of glacial acetic acid was refluxed for 5 hours. The solvent was removed and the product isolated as described in Example 1, giving the desired product as crystals, mp 148—150°C.

EP 0 129 847 B1

Example 148

Phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-methanone

A mixture of 0.02 mole of 3-ethoxy-1-(3-pyridinyl)-2-propen-1-one, 0.02 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone and 100 ml of xylene was refluxed for 12 hours. The solvent was removed and the residue dissolved in dichloromethane. This solution was dried over sodium sulfate and the product isolated as described in Example 1, as crystals, mp 202—203°C.

Example 149

2-Pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

10 A mixture of 0.10 mole of 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one and 0.20 mole of *p*-toluenesulfonic acid in 150 ml of anhydrous ethanol was refluxed for 10 hours. The solvent was removed and the residue partitioned between water and dichloromethane. The organic layer was dried over magnesium sulfate and the solvent removed, giving 3-ethoxy-1-(3-pyridinyl)-2-propen-1-one.

15 The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)-2-pyridinyl-methanone in acetic acid as described in Example 1, giving the desired product as crystals, mp 216—218°C.

Example 150

(4-Methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

20 A mixture of 0.10 mole of 3-acetylpyridine and 0.10 mole of N,N-dimethylformamide dimethylacetal in 100 ml of benzene was refluxed for 12 hours. The solvent was removed, giving 3-dibutylamino-1-(3-pyridinyl)-2-propen-1-one.

The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)(4-methylphenyl)methanone in glacial acetic acid as described in Example 1, giving the desired product as crystals, mp 203—204°C.

Example 151

(4-Methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 0.10 mole of 3-acetylpyridine and 0.10 mole of N,N-diethylformamide dimethylacetal in 100 ml of dioxane was refluxed for 10 hours. The solvent was removed, giving 3-diethylamino-1-(3-pyridinyl)-2-propen-1-one.

30 A mixture of 0.10 mole of the above compound and 0.10 mole of (3-amino-1*H*-pyrazol-4-yl)(4-methoxyphenyl)methanone in glacial acetic acid was refluxed for 6 hours. The product was isolated as described in Example 1, giving crystals, mp 193—195°C.

Example 152

2-pyridinyl[7-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

A mixture of 0.10 mole of 3-acetylpyridine and 0.10 mole of N,N-dimethylformamide dicyclohexylacetal in 100 ml of dioxane was refluxed for 8 hours. The solvent was removed *in vacuo*, giving 3-dimethylamino-1-[3-(trifluoromethyl)phenyl]-2-propen-1-one.

The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)-2-pyridinyl-methanone as described in Example 1, giving the desired product as crystals, mp 166—167°C.

Example 153

2-Pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

45 A mixture of 25 g of 3-acetylpyridine and 35 ml of N,N-dimethylformamide dipropylacetal was heated at 100°C for 6 hours. The mixture was concentrated *in vacuo* and the residue crystallized, giving 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one.

The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)-2-pyridinyl-methanone as described in Example 1, giving the desired product as crystals, mp 216—218°C.

Example 154

(4-Methylphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

To a mixture of 0.10 mole of 3-acetylpyridine in 100 ml of tetrahydrofuran was added 0.10 mole of *tert*-butoxy-bis-(dimethylamino)methane. The mixture was stirred for 24 hours and the solvent removed, giving 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one.

55 The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)(4-methylphenyl)methanone as described in Example 1, giving the desired product as crystals, mp 203—204°C.

Example 155

2-Furanyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone

60 A mixture of 0.02 mole of 3-acetylpyridine and 0.022 mole of tris(dimethylamino)methane in benzene was refluxed for 5 hours, giving 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one.

The above compound was reacted with (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone as described in Example 1, giving the desired product as crystals, mp 228—229°C.

EP 0 129 847 B1

Example 156

Phenyl[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

A mixture of 0.10 mole of 4-acetylpyridine and 40 ml of N,N-dimethylformamide diethylacetal was refluxed for 5 hours. The mixture was concentrated *in vacuo* giving 3-dimethylamino-1-(4-pyridinyl)-2-propen-1-one.

5 The above compound (0.05 mole) and 0.05 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone were reacted as described in Example 1, giving the desired product as crystals, mp 185—186°C.

Example 157

10 Phenyl[7-[(3-trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

A mixture of 0.10 mole of *m*-trifluoromethylacetophenone and 100 ml of N,N-dimethylformamide dibutylacetal was heated at 100°C for 10 hours. The mixture was concentrated *in vacuo* and the residue crystallized, giving 3-dimethylamino-1-[(3-trifluoromethyl)phenyl]-2-propen-1-one.

15 A 0.05 mole portion of the above compound was reacted with 0.05 mole of (3-amino-1*H*-pyrazol-4-yl)phenyl-methanone as described in Example 1, giving the desired product as crystals, mp 148—150°C.

Example 158

(4-Fluorophenyl)[7-(4-pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]methanone

20 A mixture of 0.10 mole of 4-acetylpyridine and 0.12 mole of N,N-dimethylformamide dibenzylacetal in benzene was refluxed for 8 hours, giving 3-dimethylamino-1-(4-pyridinyl)-*p*-propen-1-one.

A 0.05 mole portion of the above compound and 0.05 mole of (3-amino-1*H*-pyrazol-4-yl)(4-fluorophenyl)-methanone were reacted as described in Example 1, giving the desired product as crystals, mp 214—216°C.

Example 159

[7-(3-Pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]-2-thiazolyl-methanone

As described for Example 1, (3-amino-1*H*-pyrazol-4-yl)-2-thiazolyl-methanone was reacted with 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one to give the product as colorless crystals, mp 262—264°C.

Example 160

[7-(3-Pyridinyl)pyrazolo[1,5-*a*]pyrimidin-3-yl]-2-thiazolyl-methanone

As described for Example 1, (3-amino-1*H*-pyrazol-4-yl)-2-thiazolyl-methanone was reacted with 3-dimethylamino-1-(3-pyridinyl)-2-propen-1-one to give the product as crystals, mp 323—325°C.

Example 161

2-Furanyl(7-phenylpyrazolo[1,5-*a*]pyrimidin-3-yl)methanone

A mixture of 0.86 g of (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone and 0.63 g of 1-phenyl-1-propynone in 35 ml of ethanol was heated on a steam bath for one hour, then chilled in an ice bath. The solid was collected giving 0.43 g of intermediate uncyclized product, mp 190—194°C.

40 A 100 mg portion of this intermediate was heated in 20 ml of ethanol containing a catalytic amount of *p*-toluenesulfonic acid for 20 minutes on a steam bath. The solvent was removed and the residue partitioned between dichloromethane and dilute sodium hydroxide. The organic layer was heated and concentrated while adding hexane. When crystals began to form, the mixture was allowed to cool to room temperature. Filtration gave 75 mg of the desired product as off-white crystals having a melting point of 185—187°C and a pmr spectrum identical to that of the product prepared as described in Example 22.

Example 162

2-Furanyl(7-phenylpyrazolo[1,5-*a*]pyrimidin-3-yl)methanone

50 A mixture of 0.86 g of (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone and 0.63 g of 1-phenyl-1-propynone in 25 ml of ethanol with a catalytic amount of *p*-toluenesulfonic acid was heated on a steam bath for 1.5 hours. The mixture was chilled and then filtered giving 1.0 g of yellow solid. This solid was dissolved in a small amount of dichloromethane and placed on a silica gel column. The column was eluted with ethyl acetate:hexane (1:20) with a gradual change to ethyl acetate:hexane (2:5) as eluent. The column was then washed with ethyl acetate and the ethyl acetate wash was concentrated to a solid. This solid was crystallized from dichloromethane, giving 0.85 g of the desired product as cream crystals having a melting point of 188—190°C and a pmr spectrum identical to that of the product prepared as described in Example 22.

Example 163

2-Furanyl(7-phenylpyrazolo[1,5-*a*]pyrimidin-3-yl)methanone

60 A mixture of 0.86 g of (3-amino-1*H*-pyrazol-4-yl)-2-furanyl-methanone and 0.63 g of 1-phenyl-1-propynone in 35 ml of ethanol with several drops of boron trifluoride etherate was refluxed for 18 hours. The solvent was removed and the residue chromatographed on silica gel with ethyl acetate:hexane (1:20) as eluent and a gradual change to ethyl acetate:hexane (2:5). Elution with ethyl acetate gave a solid which was recrystallized from dichloromethane:hexane, giving the desired product, mp 185—187°C.

EP 0 129 847 B1

Example 164

Phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone, pyridine-1-oxide

A 1.5 g portion of phenyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone in 200 ml of dichloromethane was reacted as described in Example 132, giving 1.05 g of the desired product, mp 265—267°C.

Example 165

(4-Methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone, pyridine-1-oxide

A 1.65 g portion of (4-methoxyphenyl)[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone in 200 ml of dichloromethane was reacted as described in Example 132, giving 0.37 g of the desired product, mp 254—257°C.

Example 166

[7-[3-(Ethylamino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-2-furanylmethanone

N-(3-Acetylphenyl)-4-methylbenzenesulfonamide was prepared by the method of R. H. Vloth, *et al.*, *J. Med. Chem.*, 9, 88 (1966).

A 29 g portion of N-(3-acetylphenyl)-4-methylbenzenesulfonamide was dissolved in 250 ml of dimethylformamide with stirring. This mixture was treated with 6.5 g of sodium methoxide and stirred for 30 minutes, then 20 g of ethyl iodide was added. This mixture was stirred at room temperature for one hour, then at reflux for 5 hours. The dimethylformamide was removed *in vacuo*, the residue shaken with 150 ml of water, the mixture adjusted to pH 4 with 10N sodium hydroxide and then cooled to 0°C. The precipitate was collected, washed twice with water and then air dried, giving 31.5 g of N-(3-acetylphenyl)-N-ethyl-4-methylbenzenesulfonamide.

A 31.2 g portion of N-(3-acetylphenyl)-N-ethyl-4-methylbenzenesulfonamide and 50 ml of dimethylformamide dimethylacetal were combined and stirred on a steam bath for 18 hours, then evaporated *in vacuo* to an oil. This oil was triturated with hexane at —10°C. The hexane was decanted and the residue dissolved in 125 ml of boiling dichloromethane and then filtered. The filtrate was reheated to boiling, 200 ml of hexane was added and the mixture cooled to —10°C. The precipitate was collected, washed with hexane and dried, giving 21.6 g of N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethyl-4-methylbenzenesulfonamide.

A mixture of 5.9 g of (3-amino-1*H*-pyrazol-4-yl)-2-furanylmethanone, 12.4 g of N-[3-[3-dimethylamino]-1-oxo-2-propenyl]phenyl]-N-ethyl-4-methylbenzenesulfonamide and 200 ml of glacial acetic acid was refluxed for 18 hours, then cooled to room temperature and evaporated to dryness. The residue was partitioned between 200 ml of dichloromethane and 100 ml of saturated aqueous sodium bicarbonate. The dichloromethane layer was dried, then filtered through hydrous magnesium silicate and washed with 200 ml of dichloromethane. The filtrate and wash were combined with 200 ml of hexane, concentrated to 250 ml, diluted with 100 ml of hexane and concentrated to turbidity. A heavy oil formed which was separated and cooled to —10°C producing a solid. This solid was washed with hexane and then dried *in vacuo* at 60°C, giving N-ethyl-N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-4-methylbenzenesulfonamide.

A 10.7 g portion of N-ethyl-N-[3-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-4-methylbenzenesulfonamide was added to a mixture of 90 ml of water and 210 ml of concentrated sulfuric acid. This mixture was heated to 140—145°C, allowed to cool slowly to room temperature, then cooled to —10°C, poured onto ice, made basic with 550 ml of concentrated ammonium hydroxide and cooled to 0°C. This mixture was extracted with dichloromethane. The extract was passed through hydrous magnesium silicate and washed with 200 ml of dichloromethane. The dichloromethane filtrate and wash was combined with 300 ml of hexane, concentrated to 300 ml, diluted to 800 ml with hexane, concentrated to 300 ml, diluted to 800 ml with hexane, treated with charcoal, clarified and cooled to —10°C. This material was filtered, the filtrate concentrated to turbidity and cooled at —10°C. The precipitate was collected, washed with hexane and dried at 60°C *in vacuo*, giving 2.3 g of the desired product, mp 142—143°C.

Example 167

[7-[3-(Ethylamino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]phenylmethanone

A mixture of 6.2 g of 3-amino-1*H*-pyrazol-4-yl)-2-phenylmethanone and 12.4 g of N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethyl-4-methylbenzenesulfonamide was reacted as described in Example 166, giving 1.4 g of the desired product, mp 98—99°C.

Reference Example 1

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide

A 30.0 g portion of 3-acetamidoacetophenone was heated with 50 ml of dimethylformamide dimethylacetal on a steam bath under inert atmosphere for 8 hours. After cooling, the precipitated material was collected by filtration to yield the desired material as orange crystals (37.20 g, mp 184—185°C).

EP 0 129 847 B1

Reference Example 2

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide

In the manner of the above example, substituting 3-propanamidoacetophenone for 3-acetamidoacetophenone gave the desired product as pale orange crystals, mp 106—108°C.

Reference Example 3

N-[3-[3-Dimethylamino)-1-oxo-2-propenyl]phenyl]butanamide

In the manner of Reference Example 1, substituting 3-butanamidoacetophenone for 3-acetamidoacetophenone gave the desired compound as yellow-orange crystals, mp 113—115°C.

Reference Example 4

N-[4-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide

In the manner of Reference Example 1, substituting 4-acetamidoacetophenone for 3-acetamidoacetophenone gave the desired compound as pale yellow crystals, mp 185—186°C.

Reference Example 5

N-[4-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide

In the manner of Reference Example 1, substituting 4-propanamidoacetophenone for 3-acetamidoacetophenone gave the desired compound as yellow-orange crystals, mp 161—163°C.

Reference Example 6

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylacetamide

A solution of 4.62 g of N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide in 25 ml of dimethylformamide was stirred in an inert atmosphere and 1.0 g of sodium hydride (60% oil suspension) was added. After stirring for 1 hour, the liberation of hydrogen had ceased and a solution of 3.0 g of methyl iodide in 10 ml of dimethylformamide was gradually added (with cooling, if necessary). After stirring for an additional 1 hour at room temperature, any volatiles were removed at reduced pressure and then the reaction mixture was triturated 3 times with 100 ml of hexane. The reaction mixture was carefully poured into cold water and extracted exhaustively with methylene chloride. This material was evaporated at reduced pressure to yield a yellow-orange solid. A solution of the crude solid in methylene chloride was passed through a pad of hydrous magnesium silicate. Addition of hexane to the refluxing eluate gave crystals which were collected after cooling. The desired compound was a yellow-orange crystalline material, mp 146—148°C.

Reference Example 7

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylacetamide

In the manner of Reference Example 6 substituting ethyl iodide for methyl iodide and following the procedure outlined above, the desired compound was isolated as yellow-orange crystals, mp 110—113°C.

Reference Example 8

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylpropanamide

In the manner of Reference Example 6, substituting N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide and following the procedure outlined in Example 173, the desired product was isolated as a pale yellow crystalline solid, mp 148—149°C.

Reference Example 9

N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylpropanamide

In the manner of Reference Example 8, substituting ethyl iodide for methyl iodide and following the exact procedure in Example 173, the desired material was isolated as a yellow crystalline solid, mp 105—107°C.

Reference Example 10

N-[4-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylpropanamide

A solution of 3.10 g of N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide in 25 ml dimethylformamide was stirred in an inert atmosphere and 0.60 g of sodium hydride (60% oil suspension) was added. After stirring for 1 hour, the liberation of hydrogen had ceased and a solution of 1.8 g of methyl iodide in 5 ml of dimethylformamide was added portionwise. After stirring for an additional hour, the system was evaporated to remove volatiles and then the reaction mixture was triturated 3 times with hexane (3 x 50 ml). The reaction mixture was carefully poured into cold water and extracted with methylene chloride. The methylene chloride solution was dried and evaporated to dryness at reduced pressure to yield a crystalline solid. Recrystallization from methylene chloride-hexane gave a yellow crystalline solid, mp 76—78°C.

EP 0 129 847 B1

Reference Example 11

N-[4-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylpropanamide

In the manner of Reference Example 10, substituting ethyl iodide for methyl iodide and following the procedure outlined in that example, the desired compound was isolated as a low melting yellow-orange crystalline compound, mp 75–77°C.

Example 168

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide

A solution of 1.87 g of 3-amino-4-benzoylpyrazole and 2.32 g of N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylacetamide (Example 168) in 50 ml of glacial acetic acid was refluxed for 8 hours. The reaction mixture was evaporated to dryness and a saturated sodium bicarbonate solution was added along with 400 ml of methylene chloride. The solid that separated was recovered by filtration and was the desired compound (2.57 g, mp 205–207°C). The methylene chloride solution afforded more compound (0.73 g, mp 205–207°C).

Example 169

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide

In the manner of Example 168, substituting N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl-N-methylacetamide (Example 171) for N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylacetamide gave the desired product, mp 162–164°C.

Example 170

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide

In the manner of Example 168, substituting N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl-N-ethylacetamide (Example 174) for N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylacetamide gave the product of the example, mp 158–160°C.

Example 171

N-[3-(3-(2-Furancarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide

A solution of 1.77 g of 3-amino-4-furanylpyrazole and 2.32 g of N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl (Reference Example 1) in 50 ml of glacial acetic acid was refluxed for 10 hours. Evaporation of the reaction mixture gave a solid which was treated with a saturated sodium bicarbonate solution and 200 ml of methylene chloride. The solid that precipitated was recovered by filtration and proved to be the desired product (2.57 g, mp 195–196°C). An additional quantity of product was isolated from the methylene chloride solution, mp 195–196°C.

Example 172

N-[3-(3-(2-Furancarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide

In the manner of the above example, substituting N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl-N-methylacetamide (Example 171) for N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylacetamide gave the desired product, mp 210–212°C, which was isolated from the methylene chloride solution.

Example 173

N-Ethyl-N-[3-(3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl)]acetamide

In the manner of Example 171, substituting N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl-N-ethylacetamide (Example 174) for N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylacetamide gave the desired product isolated from the methylene chloride extract, mp 194–196°C.

Example 174

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]propanamide

A solution of 1.87 g of 3-amino-4-benzoylpyrazole and 2.46 g of N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylpropanamide (Reference Example 2) in 50 ml of glacial acetic acid was refluxed for 15 hours and then evaporated to yield a pale yellow gum. This material was partitioned between an aqueous saturated sodium bicarbonate solution and methylene chloride. The methylene chloride solution was dried with powdered anhydrous sodium sulfate and then passed through a short column of hydrous magnesium silicate adsorbent. The eluate was refluxed in a steam bath and hexane gradually added until turbidity. After cooling, the desired product was recovered by filtration (2.39 g, mp 172–174°C).

Example 175

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-methylpropanamide

In the manner of the above example substituting N-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl-N-methylpropanamide (Reference Example 8) for N-[3-(dimethylamino)-1-oxo-2-propenyl]phenylpropanamide gave the desired compound, mp 154–156°C.

EP 0 129 847 B1

Example 176

N-[3-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylpropanamide

In the manner of Example 174, substituting N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylpropanamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide gave the desired compound, mp 194—195°C.

Example 177

N-[3-(2-Furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenylpropanamide

A solution of 1.77 g 3-amino-4-furanylpyrazole and 2.46 g of N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide in 50 ml of glacial acetic acid was refluxed for 8 hours. Removal of all solvents gave a gum which was partitioned between an aqueous saturated sodium bicarbonate solution and methylene chloride. The methylene chloride extract was dried with powdered anhydrous sodium sulfate and then passed through a short column of a hydrous magnesium silicate adsorbent. The eluate was refluxed on a steam bath with gradual addition of hexanes until turbidity was noted. The desired product was collected by filtration of the cooled crystallization mixture, (2.05 g, mp 185—186°C).

Example 178

N-[3-(2-Furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl-N-methylpropanamide

In the manner of the above example, substituting N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylpropanamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide gave the desired product, mp 153—155°C.

Example 179

N-Ethyl-N-[3-(2-furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenylpropanamide

In the manner of Example 177, substituting N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylpropanamide (Example 176) for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide gave the desired compound, mp 165—167°C.

Example 180

N-(4-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenylacetamide

In the manner of Example 168, substituting N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide gave the desired compound, mp 229—231°C.

Example 181

N-[4-(3-Benzoylpyrazole[1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide

In the manner of Example 168, substituting N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylacetamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide gave the desired product, mp 173—175°C.

Example 182

N-[4-(2-Furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl-N-methylacetamide

A solution of 1.77 g of 3-amino-4-furanylpyrazole and 2.46 g of N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]-N-methylacetamide in 50 ml of glacial acetic acid was refluxed for 8 hours. Evaporation of the reaction mixture gave a gum which was partitioned between an aqueous saturated sodium bicarbonate solution and methylene chloride. The methylene chloride extract was dried and passed through a short column of hydrous magnesium silicate adsorbent. The eluate was refluxed on a steam bath with gradual addition of hexane until turbidity. On cooling, the desired compound was collected by filtration, mp 202—204°C.

Example 183

N-[4-(3-Benzoylpyrazolo[1,5-a]pyrimidin-7-yl)phenyl]propanamide

In the manner of Example 168, substituting N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]acetamide gave the desired product, mp 211—213°C.

Example 184

N-[4-(2-Furanylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenylpropanamide

In the manner of Example 177, substituting N-[4-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide for N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]phenyl]propanamide gave the desired product, mp 235—237°C.

Example 185

[5-Methyl-7-(2-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl-methanone

A mixture of 0.01 mole of 1-(2-thienyl)butan-1,3-dione was reacted with pyrrolidine in ethyl acetate to

EP 0 129 847 B1


give 3-(1-pyrrolidinyl)-1-(2-thienyl)-2-buten-1-one, mp 154–156°C.

The title compound may then be prepared as follows:

A 0.10 mole portion of the above compound and 0.10 mole of (3-amino-1*H*-pyrazol-4-yl)phenylmethane in 75 ml of glacial acetic acid is refluxed for 6 hours. The solvent is removed and the product isolated as described in Example 1.

Claims for the Contracting States: BE CH DE FR GB IT LI NL SE

1. A compound of the formula:



20 wherein R₁ is unsubstituted phenyl; phenyl mono- or di-substituted by halogen, alkoxy(C₁—C₃) or alkyl(C₁—C₃); phenyl mono-substituted by trifluoromethyl, alkylthio(C₁—C₃), alkylamino(C₁—C₅), dialkylamino(C₁—C₃), methylenedioxy, alkylsulfonyl(C₁—C₃) or alkanoylamino(C₁—C₃); naphthalenyl; thiazolyl; biphenyl; thienyl; furanyl; pyridinyl; substituted thiazolyl; substituted biphenyl; substituted thienyl; or substituted pyridinyl wherein the substituents are one or two of halogen, alkoxy(C₁—C₃) or alkyl(C₁—C₃); R₂, R₃ and R₅ are each hydrogen or alkyl(C₁—C₃); and R₃ is unsubstituted phenyl, phenyl mono-substituted by halogen, trifluoromethyl, alkoxy(C₁—C₃), amino, alkyl(C₁—C₃), alkylamino(C₁—C₅), dialkylamino(C₁—C₃), alkanoylamino(C₁—C₆), N-alkyl(C₁—C₆)alkanoylamino(C₁—C₆), cyano or alkylthio(C₁—C₃); furanyl; thienyl; pyridinyl; or pyridyl-1-oxide.

30 2. A compound according to Claim 1 wherein R_1 is 2-furanyl; R_2 , R_4 and R_5 are each hydrogen; and R_3 is 3-(trifluoromethyl)phenyl, 3-pyridinyl or 4-pyridinyl.

3. A compound according to Claim 1, wherein R₁ is unsubstituted phenyl; phenyl substituted by 4-methyl, 4-ethyl, 4-methoxy, 3,4-dimethoxy or 4-dimethylamino; 2-furanyl; 2-thienyl; 2-pyridinyl; or 4-pyridinyl; R₂, R₄ and R₅ are each hydrogen; and R₃ is 3-(trifluoromethyl)phenyl; 3-pyridinyl; 4-pyridinyl; 3-[N-alkyl(C₁—C₆)alkanoylamino(C₁—C₆)]phenyl; or 3-falkylamino(C₁—C₆)phenyl.

35 4. A compound according to Claim 1, wherein R_1 is unsubstituted phenyl; phenyl substituted by 4-fluoro, 2-fluoro, 4-methoxy, 3-fluoro, 3-trifluoro methyl or 4-methyl; R_2 , R_4 and R_5 are each hydrogen; and R_3 is 3-(trifluoro methyl)phenyl; 3-(ethylamino)phenyl; 3-pyridinyl; 4-pyridinyl or 4-pyridinyl-1-oxide.


40 5. A compound according to Claim 1, wherein R_1 is a heterocycle such as 2-thienyl, 2-furanyl, 2-thiazolyl, 2-pyridinyl or 4-pyridinyl; R_2 , R_4 and R_5 are each hydrogen; and R_3 is 3-(trifluoromethyl)phenyl, 3-(ethylamino)phenyl, 3-pyridinyl, 4-pyridinyl or 4-pyridinyl-1-oxide.

6. Use of a compound according to Claim 1 for the manufacture of a medicament for meliorating anxiety, treating epilepsy, inducing sedation or hypnosis, or inducing skeletal muscle relaxation in a mammal.

methanone; phenyl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; phenyl[7 - [3 - (trifluoromethyl)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; (4 - methoxyphenyl)[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; (3 - fluorophenyl)[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; [7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl][3 - (trifluoromethyl)phenyl]methanone; 2 - thiaryl[7 - [3 - (trifluoromethyl)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 2 - furanyl[7 - [3 - (trifluoromethyl)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 2 - furanyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; [2 - methyl - 7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]phenylmethanone; (4 - methylphenyl)[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; phenyl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone, pyridine - 1 - oxide; 2 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 2 - pyridinyl[7 - [3 - (trifluoromethyl)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 2 - pyridinyl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; [7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl - 2 - thiazolyl - methanone; 4 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 4 - pyridinyl[7 - [3 - (trifluoromethyl)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; 4 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; (2 - fluorophenyl)[7 - (3 - (trifluoromethyl)phenyl)pyrazolo[1,5 - a]pyrimidin - 3 - yl]methanone; (2 - [3 - (ethylamino)phenyl]pyrazolo[1,5 - a]pyrimidin - 3 - yl) - 2 - furanylmethanone; or [7 - [3 - (ethylamino)phenyl]pyrazolo[1,5 - a]pyrimidin-3 - yl]phenylmethanone.

EP 0 129 847 B1

8. A composition of matter in dosage unit form comprising from 2—750 mg of a compound of the formula:




wherein R₁, R₂, R₃, R₄ and R₅ are as defined in Claim 1, in association with a pharmaceutically acceptable carrier:


9. The composition of matter according to Claim 1, wherein the compound with substituent R₁ is unsubstituted phenyl; phenyl substituted by 4-fluoro, 2-fluoro, 4-methoxy, 3-fluoro, 3-trifluoromethyl or 4-methyl; R₂, R₄ and R₅ are each hydrogen; and R₃ is 3-(trifluoromethyl)phenyl; 3-(ethylamino)phenyl; 3-pyridinyl; 4-pyridinyl or 4-pyridinyl-1-oxide.

10. The composition of matter according to Claim 1, wherein the compound with substituent R₁ is a heterocycle such as 2-thienyl, 2-furanyl, 2-thiazolyl, 2-pyridinyl or 4-pyridinyl; R₂, R₄ and R₅ are each hydrogen; and R₃ is 3-(trifluoromethyl)phenyl, 3-(ethylamino)phenyl, 3-pyridinyl, 4-pyridinyl or 4-pyridinyl-1-oxide.


11. A process of preparing a compound of the formula




wherein R₁, R₂, R₃, R₄ and R₅ are as defined in Claim 1, which comprises reacting a compound of the formula



with a compound of the formula:




wherein X is O, S or NR₆ when
Y is



EP 0 129 847 B1

or $\text{C}\equiv\text{CH}$ when X is O and X is



10 when Y is chloro, bromo or Z; R_6 is alkyl ($\text{C}_1\text{--C}_6$), cyclohexyl, cyclopentyl, phenyl or $(\text{CH}_2)_m\text{-phenyl}$, where m is an integer 1—3; L and M are each $-\text{OR}_7$, or $-\text{SR}_7$, or when L and M are taken together, they form



20 where n is an integer 2 or 3 and L and M are O or S; R_7 is alkyl ($\text{C}_1\text{--C}_6$); Z is $-\text{SR}_7$, $-\text{OR}_8$, NR_9R_{10} or NHR_6 ; R_8 is hydrogen, alkyl ($\text{C}_1\text{--C}_{10}$), $-(\text{CH}_2)_m\text{-phenyl}$ where m is an integer 1—3, alkanoyl ($\text{C}_2\text{--C}_{10}$), benzoyl or carboalkoxy ($\text{C}_2\text{--C}_{10}$); R_9 and R_{10} are each hydrogen, alkyl ($\text{C}_1\text{--C}_{10}$) or phenyl or when R_9 and R_{10} are taken together with the nitrogen atom to which they are attached, they form




where p is an integer 4—6, or



where G is O, or N—D where D is alkyl ($\text{C}_1\text{--C}_6$), benzyl, benzoyl, or alkanoyl ($\text{C}_2\text{--C}_7$); under neutral or acidic conditions at 20—150°C for 1—10 hours.

35 **Claims for the Contracting State: AT**


1. A process of preparing a compound of the formula:



50 wherein R_1 is unsubstituted phenyl; phenyl mono- or di-substituted by halogen, alkoxy($\text{C}_1\text{--C}_3$) or alkyl($\text{C}_1\text{--C}_3$); phenyl mono-substituted by trifluoromethyl, alkylthio($\text{C}_1\text{--C}_3$), alkylamino($\text{C}_1\text{--C}_3$), dialkylamino($\text{C}_1\text{--C}_3$), methylenedioxy, alkylsulfonyl($\text{C}_1\text{--C}_3$) or alkanoylamino($\text{C}_1\text{--C}_3$); naphthalenyl; thiazolyl; biphenyl; thienyl; furanyl; pyridinyl; substituted thiazolyl; substituted biphenyl; substituted thienyl; or substituted pyridinyl wherein the substituents are one or two of halogen, alkoxy($\text{C}_1\text{--C}_3$) or alkyl($\text{C}_1\text{--C}_3$); R_2 , R_4 and R_5 are each hydrogen or alkyl($\text{C}_1\text{--C}_3$); and R_3 is unsubstituted phenyl, phenyl mono-substituted by halogen, trifluoromethyl, alkoxy($\text{C}_1\text{--C}_3$), amino, alkyl($\text{C}_1\text{--C}_3$), alkylamino($\text{C}_1\text{--C}_6$), dialkylamino($\text{C}_1\text{--C}_3$), alkanoylamino($\text{C}_1\text{--C}_6$), $\text{N-alkyl}(\text{C}_1\text{--C}_6)\text{alkanoylamino}(\text{C}_1\text{--C}_6)$, cyano or alkylthio($\text{C}_1\text{--C}_3$); furanyl; thienyl; pyridinyl; or pyridyl-1-oxide, which comprises reacting a compound of the formula:


60

EP 0 129 847 B1




(A)


15 with a compound of the formula:




20 wherein X is O, S or NR6 when
Y is



or C≡CH when X is O and X is



35 when Y is chloro, bromo or Z; R8 is alkyl (C1—C6), cyclohexyl, cyclopentyl, phenyl or (CH2)m-phenyl, where m is an integer 1—3; L and M are each —OR7 or —SR7, or when L and M are taken together, they form



45 where n is an integer 2 or 3 and L and M are O or S; R7 is alkyl (C1—C6); Z is —SR7, OR8, NR9R10 or NHR6; R8 is hydrogen, alkyl (C1—C10), —(CH2)m-phenyl where m is an integer 1—3, alkanoyl (C2—C10), benzoyl or carboalkoxy (C2—C10); R9 and R10 are each hydrogen, alkyl (C1—C10) or phenyl or when R9 and R10 are taken together with the nitrogen atom to which they are attached, they form




where p is an integer 4—6, or



where G is O, or N—D where D is alkyl (C1—C6), benzyl, benzoyl, or alkanoyl (C2—C7); under neutral or acidic conditions at 20—150°C for 1—10 hours.

60 2. A composition of matter in dosage unit form comprising from 2—750 mg of a compound of the formula:


EP 0 129 847 B1



wherein R₁ is unsubstituted phenyl; phenyl mono- or di-substituted by halogen, alkoxy(C₁—C₃) or alkyl(C₁—C₃); phenyl mono-substituted by trifluoromethyl, alkylthio(C₁—C₃), alkylamino(C₁—C₃), dialkylamino(C₁—C₃), methylenedioxy, alkylsulfonyl(C₁—C₃) or alkanoylamino(C₁—C₃); naphthalenyl; thiazolyl; biphenyl; thiienyl; furanyl; substituted thiazolyl; substituted biphenyl; substituted thiienyl; or substituted pyridinyl wherein the substituents are one or two of halogen, alkoxy(C₁—C₃) or alkyl(C₁—C₃); R₂, R₄ and R₅ are each hydrogen or alkyl(C₁—C₃); and R₃ is unsubstituted phenyl, phenyl mono-substituted by halogen, trifluoromethyl, alkoxy(C₁—C₃), amino, alkyl(C₁—C₃), alkylamino(C₁—C₃), dialkylamino(C₁—C₃), alkanoylamino(C₁—C₆), N-alkyl(C₁—C₆)-alkanoylamino(C₁—C₆), cyano or alkylthio(C₁—C₃); furanyl; thiienyl; pyridinyl; or pyridyl-1-oxide; in association with a pharmaceutically acceptable carrier.

Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LI NL SE

25 1. Verbindung der Formel:



wobei R₁ für unsubstituiertes Phenyl; Phenyl, das mono- oder di-substituiert ist durch Halogen, Alkoxy(C₁—C₃) oder Alkyl-(C₁—C₃); Phenyl, das monosubstituiert ist durch Trifluormethyl, Alkylthio-(C₁—C₃), Alkylamino-(C₁—C₃), Dialkylamino-(C₁—C₃), Methylenedioxy, Alkylsulfonyl-(C₁—C₃) oder Alkanoylamino-(C₁—C₃); Naphthalenyl; Thiazolyl; Biphenyl; Thiienyl; Furanyl; substituted Thiazolyl; substituted Biphenyl; substituted Thiienyl; oder substituiertes Pyridinyl steht, wobei die Substituenten ein oder zwei von Halogen, Alkoxy-(C₁—C₃) oder Alkyl-(C₁—C₃) sind; R₂, R₄ und R₅ jeweils Wasserstoff oder Alkyl-(C₁—C₃) bedeuten und R₃ für unsubstituiertes Phenyl, Phenyl monosubstituiert durch Halogen, Trifluormethyl, Alkoxy-(C₁—C₃), Amino, Alkyl-(C₁—C₃), Alkylamino-(C₁—C₃), Dialkylamino-(C₁—C₃), Alkanoylamino-(C₁—C₆), N-alkyl-(C₁—C₆)-alkanoylamino-(C₁—C₆), Cyano oder Alkylthio-(C₁—C₃); Furanyl; Thiienyl; Pyridinyl; oder Pyridyl-1-oxid steht.

2. Verbindung gemäß Anspruch 1, wobei R₁ für 2-Furanyl steht; R₂, R₄ und R₅ jeweils Wasserstoff bedeuten; und R₃ für 3-(Trifluormethyl)-phenyl, 3-Pyridinyl oder 4-Pyridinyl steht.

3. Verbindung gemäß Anspruch 1, wobei R₁ für unsubstituiertes Phenyl; Phenyl, substituiert durch 4-Methyl, 4-Ethyl, 4-Methoxy, 3,4-Dimethoxy oder 4-Dimethylamino; 2-Furanyl; 2-Thienyl; 2-Pyridinyl; oder 4-Pyridinyl steht; R₂, R₄ and R₅ jeweils Wasserstoff bedeuten; und R₃ für 3-(Trifluormethyl)-phenyl; 3-Pyridinyl; 4-Pyridinyl; 3-[N-Alkyl-(C₁—C₆)-alkanoylamino-(C₁—C₆)-phenyl; oder 3-[Alkylamino-(C₁—C₆)]-phenyl steht.

4. Verbindung gemäß Anspruch 1, wobei R₁ für unsubstituiertes Phenyl; Phenyl substituiert durch 4-Fluor, 2-Fluor, 4-Methoxy, 3-Fluor, 3-Trifluormethyl oder 4-Methyl steht; R₂, R₄ und R₅ jeweils Wasserstoff bedeuten; und R₃ für 3-(Trifluormethyl)-phenyl; 3-(Ethylamino)-phenyl; 3-Pyridinyl; 4-Pyridinyl oder 4-Pyridinyl-1-oxid steht.

5. Verbindung gemäß Anspruch 1, wobei R₁ für einen Heterocyclus wie 2-Thienyl, 2-Furanyl, 2-Thiazolyl, 2-Pyridinyl oder 4-Pyridinyl steht; R₂, R₄ und R₅ jeweils Wasserstoff bedeuten; und R₃ für 3-(Trifluormethyl)-phenyl, 3-(Ethylamino)-phenyl, 3-Pyridinyl, 4-Pyridinyl oder 4-Pyridinyl-1-oxid steht.


6. Verwendung einer Verbindung gemäß Anspruch 1 zur Herstellung eines Medikamentes für die Linderung von Angstzuständen, Behandlung von Epilepsie, Induktion von Beruhigungszuständen oder Hypnose oder Induktion von Skelettmuskelrelaxation bei einem Säuger.

7. Verwendung gemäß Anspruch 6, wobei die Verbindung Phenyl - [7 - (3 - Pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; (4 - Fluorphenyl) - [7 - (4 - - pyridinyl)pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; Phenyl - [7 - (4 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] -

EP 0 129 847 B1

methanon; Phenyl - [7 - [3 - (trifluormethyl) - phenyl -] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; (4 - Methoxyphenyl) - [7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; (3 - Fluorphenyl) - [7 - (4 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; [7 - (3 - Pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - [3 - trifluormethyl] - phenyl] - methanon; 5 2 - Thienyl - [7 - [3 - (trifluormethyl) - phenyl]pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 2 - Furanyl - [7 - [3 - (trifluormethyl) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 2 - Furanyl - [7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; [2 - Methyl - 7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - phenylmethanon; (4 - Methylphenyl) - [7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; Phenyl - [7 - (4 - pyridinyl) - pyrazolo - 10 [1,5 - a] - pyrimidin - 3 - yl] - methanon, Pyridin - 1 - oxid; 2 - Pyridinyl - [7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 2 - Pyridinyl[7 - [3 - (trifluormethyl) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 2 - Pyridinyl - [7 - (4 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 15 2 - Pyridinyl - [7 - (3 - Pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - 2 - thiazolylmethanon; 4 - Pyridinyl - [7 - (3 - pyridinyl) - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 4 - Pyridinyl - [7 - (3 - pyridinyl) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; 4 - Pyridinyl - [7 - [3 - (trifluormethyl) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; (2 - Fluorphenyl) - [7 - (3 - pyridinyl) - - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; (2 - Fluorphenyl) - [7 - [3 - (trifluormethyl) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - methanon; [7 - [3 - (Ethylamino) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - 2 - furanylmethanon; oder 20 [7 - [3 - (Ethylamino) - phenyl] - pyrazolo - [1,5 - a] - pyrimidin - 3 - yl] - phenylmethanon ist.

8. Zusammensetzung in Dosiseinheitsform, umfassend von 2 bis 750 mg einer Verbindung der Formel




wobei R₁, R₂, R₃, R₄ und R₅ wie in Anspruch 1 definiert sind, in Verbindung mit einem pharmazeutisch akzeptablen Träger.

9. Zusammensetzung gemäß Anspruch 1, wobei die Verbindung mit Substituent R₁ unsubstituiertes Phenyl; Phenylsubstituiert durch 4-Fluor, 2-Fluor, 4-Methoxy, 3-Fluor, 3-Trifluormethyl oder 4-Methyl ist; R₂, R₄ und R₅ jeweils Wasserstoff sind; und R₃ für 3-(Trifluormethyl)-phenyl; 3-(Ethylamino)-phenyl; 3-Pyridinyl; 4-Pyridinyl oder 4-Pyridinyl-1-oxid steht.

10. Zusammensetzung gemäß Anspruch 1, wobei die Verbindung mit Substituent R₁ ein Heterocyclus wie 2-Thienyl, 2-Furanyl, 2-Thiazolyl, 2-Pyridinyl oder 4-Pyridinyl ist; R₂, R₄ und R₅ jeweils Wasserstoff sind; und R₃ für 3-(Trifluormethyl)-phenyl, 3-(Ethylamino)-phenyl, 3-Pyridinyl, 4-Pyridinyl oder 4-pyridinyl-1-oxid steht.

11. Verfahren zur Herstellung einer Verbindung der Formel




wobei R₁, R₂, R₃, R₄ und R₅ wie in Anspruch 1 definiert sind, umfassend die Umsetzung einer Verbindung der Formel


60

65



EP 0 129 847 B1



15 mit einer Verbindung der Formel



wobei X für O, S oder NR6 steht, falls Y für




falls Y für Chlor, Brom oder Z steht; R6 für Alkyl-(C1—C6), Cyclohexyl, Cyclopentyl, Phenyl oder (CH2)m-Phenyl steht, wobei m eine ganze Zahl von 1 bis 3 ist; L und M jeweils für —OR, oder SR, stehen oder, falls L und M zusammengefaßt sind, die Struktur



bilden, wobei n eine ganze Zahl 2 oder 3 ist und L und M O oder S bedeuten; R7 für Alkyl-(C1—C6) steht; Z für SR7, OR8, NR9R10 oder NHR6 steht; R8 für Wasserstoff, Alkyl-(C1—C10), -(CH2)m-Phenyl, wobei m für eine ganze Zahl von 1 bis 3 steht, Alkanoyl-(C2—C10), Benzoyl oder Carboalkoxy-(C2—C10) steht; R9 und R10 jeweils für Wasserstoff, Alkyl-(C1—C10) oder Phenyl stehen oder, falls R9 und R10 zusammengefaßt sind mit dem Stickstoffatom, an das sie geknüpft sind, die Struktur



55 bilden, wobei p eine ganze Zahl von 4 bis 6 ist, oder die Struktur




wobei G für O oder N—D steht, wobei D für Alkyl-(C1—C6), Benzyl, Benzoyl oder Alkanoyl-(C2—C7) steht; unter neutralen oder sauren Bedingungen bei 20 bis 150°C während 1 bis 10 Stunden.

EP 0 129 847 B1

Patentansprüche für den Vertragsstaat: AT

1. Verfahren zur Herstellung einer Verbindung der Formel


5



15

wobei R₁ für unsubstituiertes Phenyl; Phenyl, das mono- oder di-substituiert ist durch Halogen, Alkoxy-(C₁—C₃) oder Alkyl-(C₁—C₃); Phenyl, das monosubstituiert ist durch Trifluormethyl, Alkylthio-(C₁—C₃), Alkylamino-(C₁—C₃), Dialkylamino-(C₁—C₃), Methylendioxy, Alkylsulfonyl-(C₁—C₃) oder Alkanoylamino-(C₁—C₃); Naphthalenyl; Thiazolyl; Biphenyl; Thienyl; Furanyl; Pyridinyl; substituiertes Thiazolyl; substituiertes Biphenyl; substituiertes Thienyl; oder substituiertes Pyridinyl steht, wobei die Substituenten ein oder zwei von Halogen, Alkoxy-(C₁—C₃) oder Alkyl-(C₁—C₃) sind; R₂, R₄ und R₅ jeweils Wasserstoff oder Alkyl-(C₁—C₃) bedeuten und R₃ für unsubstituiertes Phenyl, Phenyl monosubstituiert durch Halogen, Trifluormethyl, Alkoxy-(C₁—C₃), Amino, Alkyl-(C₁—C₃), Alkylamino-(C₁—C₆), Dialkylamino-(C₁—C₃), Alkanoylamino-(C₁—C₆), N-alkyl-(C₁—C₆)-alkanoylamino-(C₁—C₆), Cyano oder Alkylthio-(C₁—C₃); Furanyl; Thienyl; Pyridinyl; oder Pyridyl-1-oxid steht, umfassend die Umsetzung einer Verbindung der Formel

30




35

(A)

40


mit einer Verbindung der Formel

45



50


wobei X für O, S oder NR₆ steht, falls Y für



55

oder C≡CH steht, falls X für O steht und X für


60



65

falls Y für Chlor, Brom oder Z steht; R₆ für Alkyl-(C₁—C₆), Cyclohexyl, Cyclopentyl, Phenyl oder (CH₂)_m-Phenyl steht, wobei m eine ganze Zahl von 1 bis 3 ist; L und M jeweils für —OR₇ oder SR₇ stehen oder, falls L und M zusammengefaßt sind, die Struktur


EP 0 129 847 B1



bilden, wobei n eine ganze Zahl 2 oder 3 ist und L und M O oder S bedeuten; R₇ für Alkyl-(C₁—C₆) steht; Z für SR₇, OR₈, NR₉R₁₀ oder NHR₆ steht; R₈ für Wasserstoff, Alkyl-(C₁—C₁₀), —(CH₂)_m-Phenyl, wobei m für eine ganze Zahl von 1 bis 3 steht, Alkanoyl-(C₂—C₁₀), Benzoyl oder Carboalkoxy-(C₂—C₁₀) steht; R₉ und R₁₀ jeweils für Wasserstoff, Alkyl-(C₁—C₁₀) oder Phenyl stehen oder, falls R₉ und R₁₀ zusammengefaßt sind mit dem Stickstoffatom, an das sie geknüpft sind, die Struktur




bilden, wobei p eine ganze Zahl von 4 bis 6 ist, oder die Struktur



wobei G für O oder N—D steht, wobei D für Alkyl-(C₁—C₆), Benzyl, Benzoyl oder Alkanoyl-(C₂—C₇) steht; unter neutralen oder sauren Bedingungen bei 20 bis 150°C während 1 bis 10 Stunden.


25 2. Zusammensetzung in Dosiseinheitsform, umfassend von 2 bis 750 mg einer Verbindung der Formel



wobei R₁ für unsubstituiertes Phenyl; Phenyl, das mono- oder di-substituiert ist durch Halogen, Alkoxy-(C₁—C₃) oder Alkyl-(C₁—C₃); Phenyl, das monosubstituiert ist durch Trifluormethyl, Alkylthio-(C₁—C₃), Alkylamino-(C₁—C₃), Dialkylamino-(C₁—C₃), Methylendioxy, Alkylsulfonyl-(C₁—C₃) oder Alkanoylamino-(C₁—C₃); Naphthalenyl; Thiazolyl; Biphenyl; Thienyl; Furanyl; Pyridinyl; substituiertes Thiazolyl; substituiertes Biphenyl; substituiertes Thienyl; oder substituiertes Pyridinyl steht, wobei die Substituenten ein oder zwei von Halogen, Alkoxy-(C₁—C₃) oder Alkyl-(C₁—C₃) sind; R₂, R₄ und R₅ jeweils Wasserstoff oder Alkyl-(C₁—C₃) bedeuten und R₃ für unsubstituiertes Phenyl, Phenyl monosubstituiert durch Halogen, Trifluormethyl, Alkoxy-(C₁—C₃), Amino, Alkyl-(C₁—C₃), Alkylamino-(C₁—C₆), Dialkylamino-(C₁—C₃), Alkanoylamino-(C₁—C₆), N-alkyl-(C₁—C₆)-alkanoylamino-(C₁—C₆), Cyano oder Alkylthio-(C₁—C₃); Furanyl; Thienyl; Pyridinyl; oder Pyridyl-1-oxid steht, in Verbindung mit einem pharmazeutisch akzeptablen Träger.

Revendications pour les Etats contractants: BE CH DE FR GB IT LI NL SE

50 1. Un composé de formule:



dans laquelle R₁ est un groupe phényle non substitué; phényle mono- ou di-substitué par un halogène, un groupe alcoxy(C₁—C₃) ou alkyle(C₁—C₃); phényle mono-substitué par un groupe trifluorométhyle, alkylthio(C₁—C₃), alkylamino(C₁—C₃), dialkylamino(C₁—C₃), méthylendioxy, alkylsulfonyle(C₁—C₃) ou alkanoylamino(C₁—C₃); naphthalényle; thiazolyle; biphenyle; thiényle; furannyle; pyridinyle; thiazolyle

EP 0 129 847 B1

substitué; biphenyle substitué; thiényle substitué; ou pyridinyle substitué dans lequel les substituants comprennent un ou deux des suivants: halogène, alcoxy(C₁—C₃) ou alkyle(C₁—C₃); et R₂, R₄ et R₅ désignent chacun un atome d'hydrogène ou un groupe alkyle(C₁—C₃); et R₃ est un groupe phényle non substitué, phényle mono-substitué par un halogène, ou un groupe trifluorométhyle, alcoxy(C₁—C₃); amino, alkyle(C₁—C₃), alkylamino(C₁—C₆), dialkylamino(C₁—C₃), alcanoylamino(C₁—C₆), N-alkyl(C₁—C₆)alcanoyl-amino(C₁—C₆), cyano ou alkylthio(C₁—C₃); furannyle; thiényle; pyridinyle; ou pyridyle-1-oxyde.

5 2. Un composé selon la revendication 1, selon lequel R₁ est un groupe 2-furannyle; R₂, R₄ et R₅ désignent chacun un atome d'hydrogène; et R₃ est un groupe 3-(trifluorométhyl)phényle, 3-pyridinyle ou 4-pyridinyle.

10 3. Un composé selon la revendication 1, selon lequel R₁ est un groupe phényle non substitué; phényle substitué par un groupe 4-méthyle, 4-éthyle, 4-méthoxy, 3,4-diméthoxy ou 4-diméthylamino; 2-furannyle; 2-thiényle; 2-pyridinyle; ou 4-pyridinyle; R₂, R₄ et R₅ désignent chacun un atome d'hydrogène; et R₃ est un groupe 3-(trifluorométhyl)phényle; 3-pyridinyle; 4-pyridinyle; 3-[N-alkyl(C₁—C₆)alcanoyl-amino(C₁—C₆)]phényle; ou 3-[alkylamino(C₁—C₆)]phényle.


15 4. Un composé selon la revendication 1, selon lequel R₁ est un groupe phényle non substitué; phényle substitué par un groupe 4-fluoro, 2-fluoro, 4-méthoxy, 3-fluoro, 3-fluorométhyle ou 4-méthyle; R₂, R₄ et R₅ désignent chacun un atome d'hydrogène; et R₃ est un groupe 3-(trifluorométhyl)phényle; 3-(éthylamino)phényle; 3-pyridinyle; 4-pyridinyle ou 4-pyridinyl-1-oxyde.

20 5. Un composé selon la revendication 1, selon lequel R₁ est un hétérocycle tel que 2-thiényle, 2-furannyle, 2-thiazolyle, 2-pyridinyle ou 4-pyridinyle; R₂, R₄ et R₅ désignent chacun un atome d'hydrogène; et R₃ est un groupe 3-(trifluorométhyl)phényle, 3-(éthylamino)phényle, 3-pyridinyle, 4-pyridinyle ou 4-pyridinyl-1-oxyde.

25 6. Utilisation d'un composé selon la revendication 1 pour la fabrication d'un médicament pour améliorer l'anxiété, pour traiter l'épilepsie, pour induire la sédation ou l'hypnose, ou pour induire la relaxation musculaire du squelette chez un mammifère.

7. Utilisation selon la revendication 6, selon laquelle le composé est l'un des suivants: phényl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (4 - fluorophényl)[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; phényl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (4 - méthoxyphényl)[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (3 - fluorophényl)[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; [7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl][3 - (trifluorométhyl)phényl]méthanone; 2 - thiényl - [7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 2 - furannyl[7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 2 - furannyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; [2 - méthyl - 7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]phényl - méthanol; (4 - méthylphényl)[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; phényl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone, pyridine - 1 - oxyde; 2 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 2 - pyridinyl[7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 2 - pyridinyl[7 - (4 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; [7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 4 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 4 - pyridinyl[7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; 4 - pyridinyl[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (2 - fluorophényl)[7 - (3 - pyridinyl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (2 - (éthylamino)phényl)[7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; (2 - (éthylamino)phényl)[7 - (3 - (trifluorométhyl)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]méthanone; ou [7 - (3 - (éthylamino)phényl)pyrazolo[1,5 - a]pyrimidine - 3 - yl]phényl - méthanol.

40 8. Une composition sous forme de dosage unitaire comprenant 2—750 mg d'un composé de formule:





EP 0 129 847 B1


et R_3 est un groupe 3-(trifluorométhyl)phényle; 3-(éthylamino)phényle; 3-pyridinyle; 4-pyridinyle ou 4-pyridinyle-1-oxyde.

10. La composition selon la revendication 1, selon laquelle le composé est un composé dans lequel le substituant R_1 est un hétérocycle tel que 2-thiényle, 2-furannyle, 2-thiazolyle, 2-pyridinyle ou 4-pyridinyle; R_2 , R_4 et R_5 désignent chacun un atome d'hydrogène; et R_3 est un groupe 3-(trifluorométhyl)phényle, 3-(éthylamino)phényle, 3-pyridinyle, 4-pyridinyle ou 4-pyridinyle-1-oxyde.


11. Un procédé de préparation d'un composé de formule:




avec un composé de formule:




dans laquelle X est O, S ou NR_6 lorsque Y est



50 ou $C\equiv CH$ lorsque X est O et X est



lorsque Y est chloro, bromo ou Z; R_6 est alkyle(C_1-C_6), cyclohexyle, cyclopentyle, phényle ou $(CH_2)_m$ -phényle, où m est un nombre entier de 1-3; L et M désignent chacun $-OR$, ou $-SR$, ou lorsque L et M sont pris ensemble, ils forment le groupe



EP 0 129 847 B1

dans lequel n est un nombre entier de 2 ou 3 et L et M sont O ou S; R₇ est un groupe alkyle(C₁—C₆); Z est un groupe —SR₇, OR₈, NR₆R₁₀ ou NHR₆; R₈ est un atome d'hydrogène, un groupe alkyle(C₁—C₁₀), —(CH₂)_m—phényle où m est un nombre entier de 1—3, alcanoyle(C₂—C₁₀), benzoyle ou carboalcoxy(C₂—C₁₀); R₉ et R₁₀ désignent chacun un atome d'hydrogène, un groupe alkyle(C₁—C₁₀) ou phényle ou lorsque R₉ et R₁₀ sont pris ensemble avec l'atome d'azote auquel ils sont attachés forment le groupe




10 où p est un nombre entier de 4—6, ou




15 où G est O, ou N—D où D est un groupe alkyle(C_1 — C_6), benzyle, benzoyle ou alcanoyle(C_2 — C_7); dans des conditions neutres ou acides à 20—150°C pendant 1—10 h.

Revendications pour l'Etat contractant: AT


1. Un procédé de préparation d'un composé de formule



35 dans laquelle R_1 est un groupe phényle non substitué; phényle mono- ou di-substitué par un atome d'halogène, un groupe alcoxy(C_1 — C_3) ou alkyle(C_1 — C_3); phényle mono-substitué par un groupe trifluorométhyle, alkylthio(C_1 — C_3), alkylamino(C_1 — C_3), dialkylamino(C_1 — C_3), méthylénedioxy, alkylsulfonyle(C_1 — C_3) ou alcanoyleamino(C_1 — C_3); naphtalényle; thiazolyle; biphenyle; thiényle; furanyle; pyridinyle; thiazolyle substitué; biphenyle substitué; thiényle substitué; ou pyridinyle substitué dans lequel les substituants comprennent un ou deux des suivants: halogène, alcoxy(C_1 — C_3) ou alkyle(C_1 — C_3);
 40 R_2 , R_4 et R_5 désignent chacun un atome d'hydrogène ou un groupe alkyle(C_1 — C_3); et R_3 est un groupe phényle non substitué, phényle mono-substitué par un atome d'halogène, un groupe trifluorométhyle, alcoxy(C_1 — C_3), amino, alkyle(C_1 — C_3), alkylamino(C_1 — C_6), dialkylamino(C_1 — C_3), alcanoyleamino(C_1 — C_6), N-alkyl(C_1 — C_6)alcanoyleamino(C_1 — C_6), cyano ou alkylthio(C_1 — C_3); furanyle; thiényle; pyridinyle; ou pyridyle-1-oxyde, qui consiste à faire réagir un composé de formule:



avec un composé de formule:




65 dans laquelle X est O, S ou NR_6 lorsque

EP 0 129 847 B1

Y est


5



ou $\text{C}\equiv\text{CH}$ lorsque X est O et X est


10

15



lorsque Y est chloro, bromo ou Z; R₆ est alkyle(C₁—C₆), cyclohexyle, cyclopentyle, phényle ou (CH₂)_m-phényle, lorsque m est un nombre entier de 1—3; L et M désignent chacun —OR, ou —SR, ou lorsque L et M sont pris ensemble, ils forment le groupe

20



25

où n est un nombre entier de 2 ou 3 et L et M sont O ou S; R₇ est un groupe alkyle(C₁—C₆); Z est un groupe —SR₇, OR₈, NR₉R₁₀ ou NHR₆; R₈ est un atome d'hydrogène, un groupe alkyle(C₁—C₁₀), —(CH₂)_m-phényle où m est un nombre entier de 1—3, alcanoyle(C₂—C₁₀), benzoyle ou carboalcoxy(C₂—C₁₀); R₉ et R₁₀ désignent chacun un atome d'hydrogène, un groupe alkyle(C₁—C₁₀) ou phényle ou lorsque R₉ et R₁₀ sont pris ensemble avec l'atome d'azote auquel, ils sont attachés, ils forment le groupe



35

où p est un nombre entier de 4—6, ou




40

où G est O, ou N—D où D est un groupe alkyle(C₁—C₆), benzoyle, benzoyle, ou alcanoyle(C₂—C₇); dans des conditions neutres ou acides à 20—150°C pendant 1—10 h.

2. Une composition sous forme de dosage unitaire comprenant 2—750 mg d'un composé de formule:

45

50



55

dans laquelle R₁ est un groupe phényle non substitué; phényle mono- ou di-substitué par un atome d'halogène, un groupe alcoxy(C₁—C₃) ou alkyle(C₁—C₃); phényle mono-substitué par un groupe trifluorométhyle, alkylthio(C₁—C₃), alkylamino(C₁—C₃), dialkylamino(C₁—C₃), méthylènedioxy, alkylsulfonyle(C₁—C₃) ou alcanoyleamino(C₁—C₃); naphtalényle; thiazolyle; biphenyle; thiényle; furannyle; pyridinyle; thiazolyle substitué; biphenyle substitué; thiényle substitué; ou pyridinyle substitué dans

60

lequel les substituants comprennent un ou deux des suivants: halogène, alcoxy(C₁—C₃) ou alkyle(C₁—C₃); R₂, R₄ et R₅ désignent chacun un atome d'hydrogène ou un groupe alkyle(C₁—C₃); et R₃ est un groupe phényle non substitué, phényle mono-substitué par un atome d'halogène, un groupe trifluorométhyle, alcoxy(C₁—C₃), amino, alkyle(C₁—C₃), alkylamino(C₁—C₆), dialkylamino(C₁—C₃), alcanoyleamino(C₁—C₆), N-alkyl(C₁—C₆)alcanoyleamino(C₁—C₆), cyano ou alkylthio(C₁—C₃); furannyle; thiényle; pyridinyle; ou pyridyle-1-oxyde; en association avec un support pharmaceutiquement acceptable.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.